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Parkinson’s disease (PD) is one of the most common neurodegenerative disorders 
nowadays. This progressive, chronic and age-related pathology is characterized by a dramatic 
depletion of dopamine in the striatum due to the loss of dopaminergic neurons of the substantia 
nigra pars compacta. Despite extensive investigation aimed at finding new therapeutic 
approaches, the dopamine precursor molecule L-DOPA remains the most effective and widely 
used non-invasive therapy for PD. However, chronic treatment and disease progression cause 
the appearance of abnormal involuntary movements known as dyskinesias in the vast majority 
of patients. L-DOPA-induced dyskinesia interferes significantly with normal motor activity and 
persists unless L-DOPA dosages are reduced below therapeutic levels. Thus, controlling 
dyskinetic symptoms is one of the major challenges in PD therapy. Despite the progress made 
in recent years, the intracellular signaling mechanisms implicated in L-DOPA-induced 
dyskinesias are not fully established. 
Previous works from our laboratory demonstrated that L-DOPA-induced dyskinesia is 
causally linked with hyperstimulation of dopamine D1 receptors (D1R) located on direct 
pathway medium spiny neurons. L-DOPA activates the cAMP-dependent signalling cascade 
through the olfactory type G-protein α subunit (Gαolf), which couples D1R to adenylyl cyclase. 
Since Gαolf levels are a limiting factor for receptor signaling, we propose that Gαolf 
dysregulation could be a plausible mechanism for the D1R hypersensitivity. 
In the dopamine-depleted striatum, the hyperactivation of the cAMP-PKA signaling 
pathway (e.g., induced by L-DOPA) induces transcriptional changes resulting in increased 
expression of FosB, dynorphin-B, P-AcH3 and P-GluR1. The transcription of fosB, 
prodynorphin and as well as c-fos and Fos-related antigen-2 (fra-2) genes is repressed by 
DREAM (downstream regulatory element antagonist modulator). Based on these observations 
and on our previous data demonstrating a close association between L-DOPA-induced 
dyskinesia and overexpression of FosB and dynorphin-B, we propose that DREAM, located 
downstream of D1R-dependent cAMP/PKA activation, could play an important role in the 
cascade of molecular events leading to L-DOPA-induced dyskinesia. 
The work presented here as my PhD Thesis is primarily focused on elucidation of the 
role of dopamine and dopamine receptors in striatal Gαolf expression as well as the implication 
of DREAM protein in L-DOPA-induced dyskinesias and in the associated molecular changes. 
To achieve these aims, we used adult mice lacking D1 receptor (D1R-/-), D2 receptor 
(D2R-/-), the transcriptional factor Pitx3 (Pitx3-/-, aphakia mice), DREAM (DREAM-/-) and 
transgenic mice expressing a dominant active mutant DREAM (daDREAM) along with their 
Summary 
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wild type littermates.  
By stereotaxic procedure, mice were submitted to unilateral 6-hydroxydopamine (6-
OHDA) striatal lesions to generate an established mouse model of PD. Three weeks after the 
lesion, animals were treated daily with 25 mg/kg of L-DOPA for three weeks. Dyskinesia was 
evaluated twice a week in the hemiparkinsonian mice during chronic L-DOPA, by separately 
analyzing the four subtypes of dyskinetic symptoms using the 0-4 severity scale previously 
described. During this time, the kinetic profile of L-DOPA as well as its antiparkinsonian 
efficacy were evaluated by the rotarod and the cylinder tests. The analysis of molecular markers 
of dyskinesias was carried out by immunohistochemistry, western blot, RT-qPCR and image 
analysis.  
Immunohistochemical studies revealed the compartmentalized distribution of the Gaolf 
protein in adult mice striatum, with higher Gaolf expression in the striosomal compartment than 
in the matrix. Dopamine depletion by 6-OHDA induced a significant increase in Gaolf protein 
levels along with a loss of the described patchy pattern. Nevertheless, the increase in Gaolf 
protein was not associated with similar variations in Gaolf mRNA, which remained invariable 
after dopamine depletion. L-DOPA treatment restored both Gaolf protein levels and the 
expression pattern and induced an increase in Gαolf mRNA. These results were corroborated in 
the aphakia mice, our genetic mouse model of PD, affirming that the lesion procedure did not 
affect the results obtained in hemiparkinsonian wild type mice. 
Genetic deletion of D1R increased Gαolf protein expression in the striatum of D1R null 
mice and induced the loss of the striosomal-matrix expression pattern. Despite these changes in 
protein expression, the concentration of Gαolf transcripts was not significantly different in the 
striatum of D1R-/- mutant mice compared to their wild type littermates. These results suggest 
that modifications in Gαolf occur at a post-transcriptional level and do not result from a change 
in gene expression. Contrary to that found in the wild type animals, dopamine depletion 
significantly decreased Gαolf expression in D1R deficient mice. L-DOPA did not re-establish 
Gαolf levels in mutant mice. In addition, no patchy pattern could be detected in either 
Parkinsonian and dyskinetic models. These results indicated that D1R is necessary for the 
proper expression of Gαolf protein. 
In contrast, genetic deletion of D2R in D2R deficient mice did not affect Gαolf protein 
expression. D2R-/- mice showed the same levels and patter expression in all the three studied 
conditions, i.e., naïve, Parkinsonian and dyskinetic models. Thus, D2R does not appear to be 
implicated in the regulation of Gαolf following dopaminergic denervation and L-DOPA 
treatment. 
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We then examined whether changes downstream of D1R/cAMP signaling pathway 
could be implicated in the regulation of Gαolf expression. We found that Gαolf expression was 
maintained in DREAM-/- and in transgenic daDREAM mice despite the genetic modifications 
of DREAM. Thus, our results suggest that Gαolf levels are not regulated by D1R-dependent 
signaling downstream from cAMP stimulation.  
 However, our results indicate that DREAM protein regulates L-DOPA-induced 
dyskinesias, but does not modify basal locomotor activity and motor coordination. 
Overactivation of a dominant active version of DREAM in transgenic daDREAM mice 
dramatically reduced L-DOPA-induced dyskinesia, whereas genetic inactivation of DREAM 
increased dyskinetic symptoms. In strict correspondence with the behavioral observations, 
molecular markers of dyskinesia induced by chronic L-DOPA treatment, including FosB, 
dynorphin-B, P-AcH3 and P-GluR1, were decreased in daDREAM mice but increased in 
DREAM knockout mice. 
Importantly, DREAM modifications did not affect the kinetic profile of L-DOPA, as all 
animals showed a similar duration of the L-DOPA response. Moreover, mutant mice showed 
similar motor performance skills in the cylinder and Rota-Rod tests compared to the wild type, 
demonstrating that the antiparkinsonian efficacy of L-DOPA was preserved in mutant animals 
despite DREAM modifications. 
In summary, our results strongly suggest a homeostatic regulation of Gαolf expression 
by dopamine, with a negative correlation between their concentrations. Moreover, the data 
clearly show that whereas D2R does not influence Gαolf expression, D1R is necessary for an 
accurate regulation of both levels and pattern expression of Gαolf. These results shed light on 
the mechanisms underlying the pathophysiology of PD and L-DOPA-induced dyskinesias and 
indicate that the striosomal-matrix system plays an important role in both pathologies. 
The studies on DREAM protein demonstrate the inhibitory role of DREAM in L-DOPA
-induced dyskinesia. In addition, we demonstrated that this action occurs at least in part by 
transcriptional repression of target genes including dynorphin-B and possibly FosB, although 
non-transcriptional mechanisms could also be involved. Moreover, our data suggest that outside 
the nucleus DREAM could directly interact with the NR1 subunit and PSD-95, regulating 
activation of NMDAR and D1R. The findings we describe here validate DREAM as a novel 
therapeutic target against L-DOPA-induced dyskinesia, and we propose that specific 
modulators of DREAM could be useful in alleviating L-DOPA-induced dyskinesia without 
interfering with the antiparkinsonian effect of L-DOPA.  
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La enfermedad de Parkinson es una de las enfermedades neurodegenerativas más 
prevalentes en la actualidad. Se caracteriza por la muerte de las neuronas dopaminérgicas de la 
substantia nigra pars compacta, lo que conlleva la subsecuente depleción dopaminérgica a nivel 
estriatal. La L-DOPA constituye desde su descubrimiento a principio de la década de los 
sesenta el tratamiento de elección en la enfermedad de Parkinson, ya que es la terapia no 
invasiva más eficaz para combatir los síntomas de esta enfermedad. A pesar de sus 
considerables beneficios, la administración crónica de L-DOPA junto con el avance de la 
enfermedad provocan la aparición de movimientos involuntarios anormales conocidos como 
disquinesias en la casi totalidad de los pacientes con más de 10 años de tratamiento. La 
disquinesia interfiere con los mecanismos fisiológicos de la actividad motora y, por tanto, 
constituye el desafío más importante en la terapia antiparkinsoniana. Sin embargo, se 
desconocen en gran medida los mecanismos moleculares involucrados en las mismas. 
Trabajos previos de nuestro laboratorio demostraron que las disquinesias inducidas por 
L-DOPA están causalmente relacionadas con la hiperestimulación de los receptores 
dopaminérgicos D1 (D1R). La L-DOPA activa la vía de señalización del AMPc a través de la 
proteína Golf, la cual acopla los D1R a la enzima adenilato ciclasa. Basándonos en trabajos 
anteriores que demuestran que los niveles de la proteína Golf son uno de los factores 
limitantes para la señalización mediada por el D1R, nosotros proponemos que la regulación de 
Golf puede ser uno de los elementos implicados en la el mecanismo de hiperestimulación de 
D1R. 
 En el estriado carente de dopamina, la hiperestimulación de la vía de señalización 
de AMPc/PKA provoca cambios transcripcionales que dan lugar a la aberrante expresión de 
ciertos marcadores moleculares, como FosB, dinorfina-B, histona 3 fosforilada y la subunidad 
GluR1 del receptor AMPA. La transcripción de los genes de prodinorfina y FosB está regulada 
por la proteína DREAM (downstream regulatory element antagonist modulator) lo que nos 
permite pensar que DREAM puede jugar un papel importante en el desarrollo de las 
disquinesias inducidas por L-DOPA. 
El trabajo desarrollado durante mi doctorado se centra en dilucidar el papel de la 
dopamina y de los receptores dopaminérgicos en la expresión de la proteína Gαolf así como la 
implicación de DREAM en las disquinesias inducidas por L-DOPA y en los cambios 
moleculares asociados. 
Para llevar a cabo estos estudios se han utilizado ratones adultos knock-out de los 
receptores dopaminérgicos D1 y D2 (D1R-/- y D2R-/-), del factor de transcripción Pitx3 (Pitx3-/-
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), de DREAM (DREAM-/-) y ratones transgénicos dominantes activos de DREAM 
(daDREAM), que sobreexpresan una forma mutante de la proteína permanentemente activa. En 
todos los casos hemos contado con los respectivos animales silvestres como controles. 
Mediante técnicas estereotáxicas, los animales fueron lesionados en el estriado de forma 
unilateral con la toxina 6-hidroxidopamina (6-OHDA) para generar nuestro modelo animal de 
la enfermedad de Parkinson. Tres semanas después de la lesión, los ratones fueron tratados 
diariamente con 25 mg/kg de L-DOPA durante tres semanas. Durante este tiempo, se llevó a 
cabo la evaluación de las disquinesias (dos veces por semana), analizándose de forma 
individual las disquinesias orofaciales, de las patas delanteras y locomotoras así como la 
distonia axial mediante la escala de severidad 0-4 previamente descrita. También se evaluó el 
efecto antiparkinsoniano de la L-DOPA mediante los tests del Rota-Rod y del cilindro así como 
el estudio del perfil farmacocinético de la L-DOPA, analizando el tiempo de duración de las 
disquinesias. Tras el sacrificio de los animales por dislocación cervical o perfusión, se llevaron 
a cabo los análisis moleculares. Para ello se recurrió a técnicas de inmunohistoquímica, western 
blot, RT-qPCR y análisis de imagen. 
El estudio mediante técnicas de inmohistoquímica de la expresión de la proteína Gαolf 
mostró que en los animales silvestres existe un patrón de expresión definido, con una mayor 
concentración de Gαolf en los estriosomas que en la matriz estriatal. La depleción 
dopaminérgica estriatal mediada por la toxina 6-OHDA indujo en estos animales un aumento 
significativo en los niveles de la proteína Gαolf y una pérdida del patrón estriatal descrito. Sin 
embargo, este aumento en la concentración de la proteína no se correlacionó con un aumento en 
el ARN mensajero de Gαolf, que se mantuvo invariable. El tratamiento crónico con L-DOPA 
devolvió tanto los niveles como el patrón de expresión de Gαolf a los encontrados en la 
situación basal, mientras que por el contrario produjo un aumento en los niveles de ARNm. 
Estos resultados se corroboraron en un modelo genético para la enfermedad de 
Parkinson, los ratones Pitx3-/-. En estos ratones se reprodujeron los resultados encontrados en 
los animales hemiparkinsonianos, permitiéndonos así descartar que los cambios observados en 
los niveles de Gαolf y en su patrón de expresión fueran consecuencia del proceso de lesión. 
La deleción genética del D1R indujo un aumento de los niveles de Gαolf en el estriado 
de los ratones D1R-/-, así como la pérdida del patrón estrisoma-matriz característico. A pesar de 
estos cambios, los niveles de ARNm de Gαolf fueron los mismos en los animales knockout del 
D1R que en los animales silvestres, lo que nos indicó que los cambios en la expresión de la 
proteína se producen a nivel post-transcripcional. Al contrario de lo que encontramos en los 
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animales silvestres, la depleción dopaminérgica en los ratones D1R-/- provocó una disminución 
en la concentración de la proteína Gαolf, que no pudo ser revertida con el tratamiento con L-
DOPA. Además, en ningún caso se recuperó tampoco el patrón de expresión encontrado en los 
animales silvestres, siendo indistinguibles los estriosomas de la matriz. Esto nos permitió 
afirmar que el receptor dopaminérgico D1 es necesario para la correcta expresión de la proteína 
Gαolf. 
En contraste con estos resultados, la eliminación genética del receptor dopaminérgico 
D2 en los ratones D2R-/- no supuso cambios en la expresión de la proteína Gαolf con respecto a 
lo encontrado en los ratones silvestres, ni en la situación basal ni en condiciones parkinsonaina 
ni disquinética. Por lo tanto, el receptor dopaminérgico D2 no participa en la regulación de la 
expresión de la proteína Gαolf. 
Una vez analizada la implicación de los receptores dopaminérgicos en la expresión de la 
proteína Gαolf, estudiamos el impacto de modificaciones que tuvieran lugar más abajo en la 
cascada de señalización de las disquinesias. Para ello recurrimos a animales que sobreexpresan 
la proteína DREAM (daDREAM) y a animales que carecen de ella (DREAM-/-). En estos 
ratones mutantes no encontramos diferencias en la expresión de Gαolf con respecto a sus 
controles silvestres. Podemos por tanto afirmar que cambios por debajo del nivel de los 
receptores dopaminérgicos no alteran la expresión de la proteína Gαolf. 
En lo que a actividad motora se refiere, los estudios conductuales realizados en 
condiciones basales indicaron que las modificaciones genéticas de DREAM no alteraron ni la 
actividad ni la coordinación motora. Por el contrario, las disquinesias inducidas por L-DOPA si 
fueron diferentes en los distintos genotipos estudiados. Los ratones daDREAM mostraron 
menor grado de disquinesias durante todo el tiempo de tratamiento. En línea con estos 
resultados conductuales, la sobreactivación de DREAM en estos ratones produjo una 
disminución significativa en los marcadores de las disquinesias inducidas por L-DOPA, en 
concreto en FosB, dinorfina-B, fosfo-acetil-histona H3 y en P-GluR1. Por el contrario, la 
inactivación genética de DREAM en los ratones DREAM-/- provocó un aumento en los 
síntomas disquinéticos así como un incremento en la expresión de los marcadores moleculares.  
Cabe destacar que los animales mutantes mostraron una respuesta positiva ante el 
tratamiento con L-DOPA, mejorando sus capacidades motoras con respecto a las exhibidas en 
el estado parkinsoniano. No hubo diferencias entre genotipos indicando que las modificaciones 
en DREAM no alteran el efecto terapéutico de la L-DOPA. 
Los resultados obtenidos sobre la proteína Gαolf nos permiten afirmar que su expresión 
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está regulada por los niveles de dopamina y por el receptor dopaminérgico D1R, no el D2R. 
Esto correlaciona con resultados obtenidos en ratones tratados con cocaína, metanfetamina y 6-
OHDA. Sin embargo, es la primera vez que se reporta un cambio en el patrón de expresión de 
Gαolf como consecuencia de la denervación dopaminérgica. Nuestros resultados sugieren que 
el desequilibrio en el sistema matriz-estriosomas puede ser uno de los factores implicados en el 
desarrollo de las alteraciones relacionadas con el Parkinson, como se ha visto en otras 
alteraciones neurológicas. 
Con el trabajo realizado sobre la proteína DREAM demostramos que esta proteína tiene 
un papel modulador en las disquinesias inducidas por L-DOPA. Esta regulación ocurre al 
menos en parte a nivel de represión transcripcional de los genes de FosB y dynorfina-B, aunque 
también participan procesos no transcripcionales como la interacción directa de DREAM con 
PSD-95 y con la subunidad NR1 de los receptores NMDA. Estos resultados nos permiten 
sugerir que moduladores específicos de DREAM podrían ser útiles para aliviar las disquinesias 
inducidas por L-DOPA, sin que interfieran con el efecto terapéutico de la L-DOPA.  
Introduction 

                                                                                                                                    Introduction 
19 
1. THE BASAL GANGLIA 
The basal ganglia comprise a collection of subcortical structures involved in the control 
of motor and limbic functions including learning, memory and cognitive processes. This 
breadth of functions is strikingly exhibited in the range of clinical disorders related to basal 
ganglia alterations, such as Parkinson’s disease (PD), Huntington’s disease, attention-deficit 
hyperactivity disorder, compulsivity and obsessive-compulsive disorder and depression. The 
functionally connected nuclei that conform the basal ganglia belong to the forebrain, 
diencephalon and midbrain and include the striatum (caudate and putamen), the globus pallidus 
pars externa (GPe) and pars interna (GPi), the subthalamic nucleus (STN) and the substantia 
nigra, divided into its pars compacta (SNc) and pars reticulata (SNr). Together, all these 
interconnected nuclei form a highly organized and complex circuitry.  
The first model of motor circuit of the basal ganglia was developed at the end of the 
1980s (Penney and Young, 1986; Albin et al., 1989; DeLong, 1990). According to this model, 
information from the cerebral cortex and thalamus is integrated in the striatum. The processed 
information is send to the SNr, to provide feed-back via the ventral thalamus to the cerebral 
cortex, forming parallel cortico-basal ganglia-thalamo-cortical loops (Lanciego et al., 2012) 
(Figure 1). 
Figure 1. Schema of the cortico-basal ganglia-thalamocortical loop in the mouse brain. Sagital section of 
mouse brain stained with tyrosine hydroxylase antibody. Abbreviations: LGP: Lateral Globus Pallidus; SNc: Sub-
stantia nigra pars compacta; SNr: Substantia nigra pars reticulata and STN: Subthalamic Nucleus.    
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The striatum sends the processed information through two parallel and diametrically 
opposed GABAergic pathways: the direct or striatonigral patway, which projects to the SNr 
and the GPi; and the indirect or striatopallidal patway, which projects to the SNr and the GPi 
indirectly, via GPe and STN. The direct and indirect pathways exert opposing effects on 
movements and an imbalance in their activity is believed to lead to hypokinetic (i.e., 
Parkinsonism) or hyperkinetic (i.e., dyskinesia) movement disorders.  
Current thinking has modified this functional model, including several loops that 
interact with internal reentry loops (Figure 2). The cortico-subthalamo-pallidal hyperdirect 
pathway bypasses the striatum, being the fastest route by which cortical and thalamic 
information can modulate the SNr/GPi activity (Nambu et al., 2002; Rico et al., 2010). 
Moreover, reciprocal connections between the GPe and the striatum (Sato et al., 2000) and 
between the striatum and dopamine neurons in the SNc (Haber et al., 2000) have been 
described.  
Figure 2. Simplified view of the motor circuit of the basal ganglia. Red arrows indicate inhibitory GABAergic 
connections; green arrows, excitatory glutamatergic connections. Abbreviations: GPe, globus pallidus pars externa; 
GPi, globus pallidus pars interna; PPN, pedunculopontine nucleus; SNc, substantia nigra pars compacta; SNr, sub-
stantia nigra pars reticulta; STN, subthalamic nucleus. Adapted from DeLong and Wichmann, 2007. 
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2. THE STRIATUM 
The striatum is the primary input nucleus of the basal ganglia. The striatum is located in 
the forebrain and its name comes from its striped appearance, due to the myelinated axons that 
cross it. In higher vertebrates, the striatum is composed of the caudate nucleus and the putamen, 
separated by the internal capsule. In rodents, it appears as a single nucleus. Topographically, the 
striatum can be divided into the dorsal (caudate-putamen) and the ventral (nucleus accumbens, 
NAc) striatum. The dorsal part receives cortical input from neocortex, processing sensorimotor 
information, whereas ventral striatum receives cortical inputs from allocortical, periallocortical 
and proisocortical regions and processes mostly reward-related information.  
2.1 Striosome and matrix organization 
In addition to the topographical organization of the mammalian striatum, two different 
tissue compartments have been clearly identified from neurochemical and developmental points 
of view: the striosomes (or patches) and the matrix compartments (Graybiel, 1990). Striosomes 
were first recognized as compartments of low acetylcholinesterase activity (Graybiel and 
Ragsdale, 1978) and characterized by light or poor calbindin zones (Davis and Puhl, 2011; 
Watabe-Uchida et al., 2012) and limited parvalbumin staining (Prensa et al., 1999). In contrast, 
striosomal neurons are rich in µ-opiate receptors 1 (MOR1) (Breuer et al., 2005; Lawhorn et 
al., 2009; Tajima and Fukuda, 2013), dopamine D1 receptors (Kim et al., 2002) and olfactory 
type G-protein α subunit (Gαolf) (Sako et al., 2010). Taking advantage of these neurochemical 
characteristics, a recent study shows by immunohistochemistry a site-dependent diversity of 
mice striosomes along both the rostrocaudal and dorsoventral axes of the striatum based upon 
the distribution of staining patterns (Tajima and Fukuda, 2013). From a developmental point of 
view, striosomes are established earlier than the matrix components (Graybiel and Hickey, 
1982; Crittenden and Graybiel, 2011) and represents approximately 15% of the total striatal 
volume.  
The striosomes mainly receive and process limbic and reward-related information 
(White and Hiroi, 1998) whereas the matrix mainly received associative and sensorimotor 
information (Gerfen, 1984). In addition, striosomes are thought to contain the only striatal 
neurons that have direct projections to the dopamine-containing cells of the SNc, regulating the 
nigral input to the striatum. Thus, striosomes are thought to influence striatal processing by 
exchanging information with the surrounding matrix (Crittenden and Graybiel, 2011).  
Differential activation and susceptibility of both compartments have been reported. 
Interestingly, matrix neurons showed a higher metabolic activity during natural behavioural 
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states such as rest or free moving (Brown et al., 2002). In contrast, chronic cocaine or 
amphetamine treatments that lead to a stereotypic behaviour preferentially activate the 
striosomal compartment (Moratalla et al., 1996a). A relative increase of striosomal activity 
largely due to decreased matrix activity could be linked with the development of stereotypy 
(Tanimura et al., 2011). Moreover, striosomal dopaminergic terminals have been found to be 
more susceptible to the neurotoxicity induced by MDMA and methamphetamine than the 
surrounding matrix (Granado et al., 2008a; 2010) (Figure 3). Taken together, imbalances 
between striosomes and matrix functions could be directly related with neurological disorders, 
including PD, Huntington’s disease, dystonia and drug addiction (Granado et al., 2008a; 
Crittenden and Graybiel, 2011).  
Figure 3. TH and DAT loss takes place preferentially in the striosomal compartment after methampheta-
mine treatment. Serially adjacent brain sections from mouse treated with methamphetamine stained for tyrosine 
hydroxylase (TH), μ receptor opioid 1 (MOR) and dopamine transporter (DAT). Patches of weak TH- and DAT-
positive fibres correspond with  striosomes identified by MOR immunostaining. From Granado et al., 2010. 
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2.2  Neuronal components 
The striatum is composed of one principal neuron cell type, the medium spiny 
projection neurons, accounting for 90-95% of total striatal neurons in rodents and 75-80% in 
primates (Kemp and Powell, 1971). The remaining striatal neurons are interneurons (DiFiglia et 
al., 1976; Kawaguchi et al., 1995). 
-  Projection neurons 
Medium spiny projection neurons (MSN) take their name from their morphological 
appearance, with a medium-sized (20-25 µm) rounded or oval cell body, large axons and 
multiple spiny dendrites (Figure 4). All the projection neurons in the striatum are GABAergic 
and morphologically identical but two major subpopulations of approximately equal number 
may be defined on the basis of their projection targets and the expression of distinct 
neuropeptides and receptors (Gerfen and Surmeier, 2011): 
 Direct pathway or striatonigral neurons, projecting to the substantia nigra. They express 
substance P, dynorphin and dopamine D1 receptor (D1R). 
 Indirect pathway or striatopallidal neurons, projecting to the globus pallidus. They 
express enkephalin, adenosine A2a receptors (A2aR) and dopamine D2 receptor (D2R). 
Activation of direct pathway D1R-neurons facilitates movements, whereas activity in 
the indirect pathway D2R-neurons inhibits motor function. The extended view of the 
anatomical organization of the striatum is that both direct and indirect neurons are intermingled 
throughout the striatum, displaying a uniform organization. Pioneering work with in situ 
hybridization pointed out the segregation of D1R and D2R in striatonigral and striatopallidal 
projection neurons, respectively (Le Moine et al., 1990a, 1991). These results were challenged 
on the basis of single cell mRNA expression studies, which reported colocalization of both 
dopamine receptor subtypes in striatal neurons (Surmeier et al., 1992). However, nowadays the 
segregation of the two populations had been solid establish with bacterial chromosome artificial 
(BAC) transgenic mice. These new mouse lines, in which enhanced fluo-rescent proteins are 
driven by D1R or D2R promoters, provide an easy way to label neurons which express high 
levels of D1R or D2R (Valjent et al., 2009). In mice carrying BAC drd1a-GFP or drd1a-
Tomato (a red fluorescent protein), striatonigral D1R-positive projection neurons are labeled, 
whereas striatopallidal D2R-positive projection neurons are stained in BAC drd2-GFP mice 
(Matamales et al., 2009; Bertran-Gonzalez et al., 2010). 
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-  Interneurons 
Striatal interneurons make up some 5-10% of the total striatal neuron population in 
rodents. They have short aspiny axons, which project within but never out of the striatum. 
Striatal interneurons may be classified depending on their cytochemical and morphological 
characteristics into large cholinergic cells and medium-sized GABAergic cells. Large 
cholinergic interneurons have a large polygonal or fusiform soma (20-50 µm) and release 
acetylcholine. They are the only tonically active neurons in the striatum (Aosaki et al., 1994) 
and abundantly express dopamine D5 receptors (D5R) (Rivera et al., 2002a). Medium-sized 
GABAergic neurons can be further divided into: 1) parvalbumin-containing, 2) calretinin-
containing, and 3) somatostatin-, neuropeptide Y-, and nitric oxide synthase-containing 
interneurons. 
Figure 4. Medium spiny projection neurons. (A) Single MSN labeled with Lucifer Yellow. Note the high num-
ber of spines. From Suárez et al., 2014. (B) Confocal section of D1R-Tomato/D2R-GFP BAC-transgenic mice 
striatum. Note the intermingled and segregated anatomical disposition of both MSN in the striatum, with no colo-
calization. From Ares-Santos et al., 2014. 
2.3 Dopamine receptors  
Dopamine is a major catecholamine in the brain. Some 80% of dopamine in the brain is 
localized in the striatum, where their receptors are mostly expressed. Dopamine receptors 
belong to the superfamily of G protein-coupled receptors (GPCRs). They have seven 
transmembrane domains and include five different receptor subtypes. These dopamine receptor 
subtypes are encoded by genes with different chromosomal loci and display considerable 
homology in their structure.  
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The D1-like receptors family includes D1R and D5R, which are associated with 
excitatory function. Both D1R and D5R are positively coupled to adenylyl cyclase (AC), the 
enzyme responsible for the conversion of ATP into cAMP. D1R is mainly expressed in the 
striatum, NAc, cerebral cortex, olfactory tubercule, SN and amygadala, while D5R is primarily 
expressed in the cerebral cortex, hippocampus, striatum, lateral mammillary nucleus, and in the 
parafascicular nucleus of the thalamus (Rivera et al., 2002a).  
On the other hand, the D2-like receptors family includes D2R, D3R and D4R. They are 
negatively coupled to AC and generally have inhibitory function. D2R is abundant in typical 
dopamine rich areas such as the striatum, olfactory tubercule, NAc, SNc and VTA. It is mostly 
expressed in striatopallidal neurons but also found in cholinergic neurons (Le Moine et al., 
1990b). The D2R subtype has two splice variants coded by the same gene, the long form (D2L) 
and the short form (D2S). These two receptors have distinct functions in vivo; D2L acts mainly 
at postsynaptic sites and D2S serves presynaptic autoreceptor functions in the soma of 
dopaminergic neurons of the SNc (Usiello et al., 2000; Anzalone et al., 2012). D3R in the rat 
brain is restricted to a few brain regions including ventral striatum and SNc (Xu et al., 1997). 
D4R appears to be highly expressed in the frontal cortex, amygdala, olfactory bulb, 
hippocampus, hypothalamus and mesencephalon (Rivera et al., 2002b). 
2.4 G proteins coupled to dopamine receptors 
The opposing actions of D1- and D2-like receptors result from their different coupling 
to G protein subunits. G proteins comprise three subunits, α, β and γ, forming a heterotrimeric 
complex attached to the membrane. Upon binding to dopamine, GPCRs undergo 
conformational changes that activate their ability to catalyze the exchange of GDP with GTP. 
GTP binding to the α subunit causes its dissociation from the βγ complex. Both the active form 
of the Gα (GTP-bound) and free Gβγ interact with a range of downstream signaling molecules 
and modulate their activity to generate cellular responses. Depending on their role in AC 
activity, we can differentiate stimulatory and inhibitory Gα subunits. D1-like receptors are 
coupled to stimulatory Gα (Gαs/olf), activating AC; whereas D2-like receptors are coupled to 
inhibitory Gα subunit (Gαi/o), inhibiting AC. 
Two highly homologous Gα subunits are known to activate AC: Gαs, the ubiquitous 
isoform, which is found in most cell types, and Gαolf (i.e., olfactory type G-protein α subunit), 
which has been discovered in the rat olfactory epithelium and mediates olfactory receptor 
signaling (Jones and Reed, 1989; Belluscio et al., 1998). Gαolf is present in much higher 
quantities than Gαs in the striatum (Drinnan et al., 1991; Hervé et al., 1993). There, Gαolf 
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colocalizes with D1R and mediates their coupling to AC (Hervé et al., 1993; Corvol et al., 
2001). In addition, Gαolf also colocalizes with A2aR, located in D2R-bearing neurons (Kull et 
al., 2000; Hervé et al., 2001). Thereby, Gαolf subunit protein is present in both types of MSN 
in the striatum, coupled to D1R in the striatonigral neurons and to A2aR in the striatopallidal 
ones. Interestingly, Gαolf protein expression is selectively increased in either D1R or A2aR 
knockout mice (Hervé et al., 2001). These changes have been seen to occur in a post-
transcriptional level and do not result from a change in gene expression. In line with these 
findings, deletion of dopamine transporter (DAT) and subsequent hyperstimulation of 
dopamine receptors, results in a decrease of Gαolf protein in the striatum. Taken together, these 
results indicate that receptor usage and dopamine tone may control Gαolf levels.  
3.   PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with multifactorial 
etiology characterized by the loss of nigrostriatal dopaminergic neurons within the midbrain, 
particularly SNc. PD is the second most common age-related neurodegenerative disease after 
Alzheimer’s disease, affecting more than 4 million people worldwide (de Lau and Breteler, 
2006). The age of onset is usually over 60, but it is estimated that one in ten people are 
diagnosed before the age of 50, with slightly more men than women affected (European 
Parkinson’s Disease Association, EPDA). PD was originally described in 1817 by the British 
physician James Parkinson in the classic monograph "Essay on the Shaking Palsy". PD was 
then known as shaking palsy or paralysis agitans; the term "Parkinson's disease" was introduced 
later by Jean-Martin Charcot. All the cardinal signs of PD relate to motor dysfunction and 
include resting tremor, bradykinesia, rigidity and postural reflex impairment. 
3.1 Etiology and epidemiology 
After many years of intense research, little is still known about the etiology of PD. In 
the last decade, perhaps the greatest single advance in the PD field has been the identification of 
genes that increase disease risk (Gasser, 2009). At present, 16 loci have been clearly linked to 
familial forms of PD (Lees et al., 2009; Puschmann, 2013; Singleton et al., 2013). However, 
these still account for less than 10-15% of all the cases of PD and most of the PD-associated 
genes are of unknown or poorly understood function. Thus, the cause of sporadic PD, which 
accounts for about 85-90% of all PD subjects, still remains uncertain. Current understanding of 
the etiology of sporadic PD points to multifactorial causes, combining genetic, age and 
environmental factors. Most cases of PD may be due to a double hit involving an interaction 
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between a gene mutation that induces susceptibility coupled with to a toxic environmental 
factor. 
The strongest risk factor in PD is age. Disease incidence rises exponentially above the 
age of 65. Why age is such a strong risk factor is unknown, but it is widely speculated that 
declining mitochondrial function is a key factor (Schapira, 2008; Boumezbeur et al., 2010). 
Others factors associated with an increased risk for PD are exposure to pesticides and metals, 
vascular/metabolic diseases, stress and infections as encephalitis. Factors proposed to protect 
against the development of PD include antioxidants, cigarette smoking, coffee, tea and wine 
drinking, Mediterranean diet and high physical activity. 
3.2 Neuropathological features 
The progressive degeneration of the dopaminergic neurons in the SNc and the 
appearance of intracytoplasmic inclusions called Lewy bodies (LB) represent the main 
neuropathological features of PD (Greenfield and Bosanquet, 1953; Braak et al., 2002; 2003; 
Tong et al., 2010). Neuronal loss in the SNc is not uniform; the neurons of the ventrolateral tier, 
which project to the striatum, and are involved in motor disorders, are selectively more 
vulnerable than the others. In contrast, dorsal neurons may be vulnerable to age-related 
neuronal degeneration and their loss is never as severe as that detected in PD. The medial 
neuronal groups, i.e. mesolimbic dopaminergic neurons in the VTA, may be affected in patients 
with dementia. The selective vulnerability of dopaminergic neurons in the ventral SNc has been 
suggested to be due to their uniquely massive, unmyelinated axonal arbor (Bolam and 
Pissadaki, 2012). The extreme bioenergetics demand of maintaining the massive number of 
synapses and the immense axonal field that these neurons give raise to makes them especially 
vulnerable to stressors of any sort. 
Approximately 3.6% of remaining neurons in the SNc contain LB (Greffard et al., 
2010), which are composed of alpha-synuclein associated with other proteins such as ubiquitin. 
Interestingly, the proportion of LB-bearing neurons remains roughly constant. Nowadays, the 
precise reason why LB develops is not known and their role in neuronal degeneration remains 
controversial. While some authors postulate that LB represent a form of aggresome that 
develops in response to increased levels of misfolded proteins to segregate and facilitate the 
clearance of these potentially toxic proteins (Manning-Bog et al., 2003; Calne and Mizuno 
2004; Tanaka et al., 2004), others report a toxic effect and a contribution to neurodegeneration 
by LB (Greffard et al., 2010). Correlating with this later idea, Dr. Vila’s group has recently 
demonstrated that intranigral or intrastriatal inoculations of PD-derived LB extracts monkeys 
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and mice resulted in progressive nigrostriatal neurodegeneration starting at striatal 
dopaminergic terminals (Recasens et al., 2014). 
In 2003 Heiko Braak and coworkers established a chronopathological model of PD 
based in the appearance of LB with a sequential and predictable fashion (Braak et al., 2003). 
According to Braak’s model, pathological process begins in the olfactory system, peripheral 
autonomic nervous system and dorsal motor nucleus of the vagus, extending as an oil drop to 
involve dopamine neurons of the SNc in the mid-stage of the disease, and affecting the cerebral 
hemispheres in the latter stages of the illness. While this precise sequence of degeneration may 
not apply to all cases, it raises the possibility that neurodegeneration might extent from affected 
to unaffected areas in a prion-like manner (Olanow and Brundin, 2013). 
3.3 Changes in basal ganglia motor circuitry in PD 
The degeneration of dopaminergic neurons in the SNc leads to a consequent striatal 
denervation responsible for the major symptoms of disease. This loss first affects the caudal, 
mainly sensorimotor, part of the striatum (Kish et al., 1988; Moratalla et al., 1992). Loss of 
striatal dopamine causes a profound imbalance between the two main striatal pathways. 
Dopaminergic depletion in PD reduces the activation of striatonigral neurons of the direct 
pathway while enhances the activation of striatopallidal projection neurons of the indirect 
pathway, leading to increased activity of the STN, which in turns overactivates inhibitory 
output neurons in the GPi/SNr. In this way, the combined reduction of GABA inhibition from 
the “direct” striatal output neurons and increased glutamatergic drive from the disinhibited STN 
leads to increased activity in the GPi/SNr output neurons, reducing their inhibitory activity and 
thereby impeding movement initiation and execution (Obeso et al., 2013; Figure 5). This 
imbalance was first documented in anatomo-functional studies (Gerfen et al., 1990; Gerfen, 
2000) and later confirmed by electrophysiological experiments (Mallet et al., 2006). More 
recently, Kreitzer’s group has examined the behavioral effects of specifically activating by laser
-illumination the direct or the indirect pathway in awake mice using an optogenetical approach 
(Kravitz et al., 2010). They showed that bilateral excitation of indirect-pathway neurons elicited 
a Parkinsonian state, characterized by freezing and bradykinesia, while activation of direct-
pathway neurons increased locomotion. Interestingly, in a mouse model of PD, direct pathway 
activation completely rescued deficits in freezing, bradykinesia, and locomotor initiation. 
At the receptor level, dopamine depletion induces an increase in the number of D2R in 
striatopallidal neurons (Creese et al., 1977; Cai et al., 2002) while no significant changes and 
even a decrease in D1R density is found (Gerfen et al., 1990; Hervé et al., 1992; Hurley et al., 
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2001). Chronic interruption of nigrostriatal dopaminergic pathway in PD increases the 
sensitivity of striatal D1R and D2R in response to receptor stimulation (Arnt and Hyttel, 1985). 
This hyper-responsiveness is attributed to elevated levels and efficiency of Gαolf after 
dopamine denervation (Marcotte et al., 1994; Corvol et al., 2004; Aubert et al., 2005). Thus, 
the ability of dopamine to stimulate AC and PKA via activation of D1R is enhanced in PD 
patients and in experimental animals following dopamine depletion (Tong et al., 2004; Santini 
et al., 2008). 
Figure 5. Simplified diagram of basal ganglia motor circuit in healthy and Parkinsonian state. (A) In healthy 
conditions, the balance between direct and indirect pathways inputs to the BG output structures is regulated by a 
normal dopamine signal. (B) In Parkinsonian state, the lack of dopamine stimulation in the striatum induces re-
duced activity of the direct pathway and increased activity of the indirect pathway, resulting in a final overactivity 
of the GPi/SNr and a sustained inhibition of the thalamocortical circuits. Abbreviations: GPe, globus pallidus pars 
externa; GPi, globus pallidus pars interna; SNc, substantia nigra pars compacta; SNr, substantia nigra pars re-
ticulta; STN, subthalamic nucleus. Adapted from Jenner, 2008 and Lanciego, 2012. 
3.4 Clinical features 
PD clinical manifestations begin when dopamine concentrations in the striatum fall 
below 70% and more than the 50% of SNc dopaminergic neurons have been lost (Iravani et al., 
2012). The accepted criteria for a clinical diagnosis of PD include the presence of two of the 
three classical motor features (rest tremor, rigidity and bradykinesia), unilateral onset, a strong 
clinical response to L-DOPA and the absence of features suggestive of any other motor 
disorders. 
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-  Motor features 
Rest tremor is the most obvious manifestation of PD, occurring in approximately 70% 
of patients. The typical tremor in PD is a rest tremor, presented mainly when the patient is 
relaxed and when the tremulous limb is not engaged in purposeful activities. It tends to start 
unilaterally in the hand, subsequently involving the ipsilateral leg or the contralateral arm. On 
average, the tremor spreads bilaterally 6 years after the onset of the symptoms and the side 
initially affected continues to have more tremor than the contralateral side (Rodriguez-Oroz et 
al., 2009). 
Rigidity is characterized by unvarying increased resistance to passive limb movement, 
due to stiffness or inflexibility of the muscles. It is accompanied by cramps and pain. Rigidity 
occurs in 89-99% of patients with PD and responds better to L-DOPA treatment than the other 
two classical motor features of PD.  
Bradykinesia, meaning slowness of movements, is the major cause of disability in PD 
and is eventually seen in all patients. In general, bradykinesia manifests first as a delay in the 
initiation of movement and is responsible for many characteristic symptoms of PD, such as 
micrographia, hypophonia (weak voice or whispering), masked face and drooling, decreased 
blink rate and slow shuffling gait.  
- Non-motor features 
Non-motor symptoms may include depression and anxiety, sleep disturbance, olfactory 
dysfunction, behavioral and cognitive impairment and autonomic dysfunction, such as urinary 
difficulties, constipation, sexual disturbances and cardiovascular changes (Chaudhuri and 
Schapira, 2009). The appearance of some of these symptoms precedes the development of the 
classic motor effects. 
3.5 Treatment 
Presently, despite extensive investigation aimed at finding new therapeutic approaches 
that slow or reverse the progression of the disease, PD is still incurable and progressive. 
However, therapeutic strategies to control motor symptoms are wide and include a high variety 
of pharmacologic agents as well as surgical treatments. 
- L-DOPA 
3,4-dyhydroxyphenyl-L-alanine (L-DOPA) remains the most effective and noninvasive 
therapy for alleviating motor symptoms in PD (Figure 6). As a precursor of dopamine, L-DOPA 
crosses the blood-brain barrier via neutral amino acid transporters. It is decarboxylated to 
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dopamine in the nigrostriatal pathway by dopa-decarboxylase before being stored in synaptic 
vesicles for subsequent release. In the peripheral system, dopamine provokes prominent adverse 
side effects, especially nausea and hypotension, limiting the utility of L-DOPA when it was first 
introduced. For that reason, L-DOPA is most commonly used in combination with a peripheral 
decarboxylase inhibitor, carbidopa or benserazide, which do not cross the blood-brain barrier 
and hence selectively block conversion of L-DOPA to dopamine outside the brain. The precise 
places where L-DOPA is decarboxylated in the Parkinsonian brain remains unclear, as most 
striatal dopamine terminals are degenerated. It has been postulated that exogenous L-DOPA can 
be decarboxylated and released as dopamine by serotonin terminals, striatal capillaries, 
noradrenergic neurons, and monoaminergic striatal interneurons (Bezard et al., 2013) as well as 
in tyroxine hydroxylase (TH)-containing striatal neurons (Darmopil et al., 2008; Espadas et al., 
2012). In addition, L-DOPA produces some pharmacological actions not through conversion to 
dopamine (Porras et al., 2014) including antiparkinsonian effect (Alachkar et al., 2010).  
Figure 6. Reversal of dopamine depletion by L-DOPA. (A) Chemical formula and (B) three-dimension structure 
of L-DOPA. (C) Rabbits treated with reserpine before (top) and after (bottom) L-DOPA administration. Adapted 
from Carlsson, 2001. Carlsson was awarded the Nobel Prize in Physiology or Medicine in 2000 for his works on 
dopamine. In 1957, Carlsson and colleagues described for the first time that L-DOPA treatment restores the Park-
insonism induced by reserpine. It took another 10 years for L-DOPA to become the standard for the treatment of 
PD. The first large study reporting improvements in PD patients treated with L-DOPA was published in 1968 
(Cotzias, 1968). 
Initial treatment with L-DOPA leads to an effective and sustained control of motor 
symptoms of PD during a period of time often referred to as the “honeymoon period” which 
may last for up to 5 years. However, chronic pulsatile administration of L-DOPA and disease 
progression lead to a shorter, more unpredictable and inadequate response that results in motor 
complications in approximately 70 % of patients within 6 years of initiation of treatment. These 
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motor complications include a shortened duration of drug benefit termed “wearing off” and 
drug-induced abnormal involuntary movements known as dyskinesias (Obeso et al., 2000; 
Pavón et al., 2006; Stocchi et al., 2010). The “wearing off” state in which a formerly effective 
dose is no longer as effective as before and PD symptoms return occurs when the plasma levels 
of L-DOPA decline (Figure 7). Over time, this phenomenon becomes more frequent as benefits 
of each dose become shorter, leading the onset of “wearing off” state before the next dose of L-
DOPA. On the other hand, dyskinesias may occur at the time of maximal clinical benefit and 
peak concentration of L-DOPA (peak dose dyskinesias) or appear at the beginning and at the 
end of the dose (diphasic dyskinesias). The mechanisms by which dyskinesias develop are not 
yet fully understood but pulsatile stimulation of dopamine receptors and progressive striatal 
denervation are implicated. 
These complications can be an important source of disability for some patients and in 
fact, they are the main cause of treatment discontinuation. Therefore, dyskinesias represent one 
of the main challenges to the symptomatic antiparkinsonian therapy. 
Figure 7. Changes in L-DOPA response over time. Early PD is associated with a prolonged response to L-
DOPA. Chronic treatment and disease progression lead to a shorter duration of action with wearing off of motor 
benefit prior to the next dose. Peak dose dyskinesias begin to appear. As neurodegeneration advances and the ad-
verse effects of L-DOPA accrue, clinical response becomes ever shorter and unpredictable, with more pronounced 
dyskinesias. Modified from Schapira et al., 2009. 
-  Other treatments 
Dopamine agonists are being used as monotherapy in early PD or in combination with L
-DOPA in more advanced stage. They are more frequently chosen as initial therapy for PD in 
younger patients (<50 years of age), to help delay L-DOPA treatment. The mechanism of action 
of dopamine agonists involves direct stimulation of dopamine receptors. The list of dopamine 
agonists used today is wide and includes ergoline compounds, such as bromocriptine, pergolide, 
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cabergoline and lisuride, and nonergoline compounds, such as pramipexole, ropinirole, 
rotigotine, piribedil and apomorphine. Dopamine agonists are more likely than L-DOPA to 
cause cognitive side effects, such as confusion, hallucinations and impulse-control disorders. 
The dopamine metabolism inhibitors are used in conjunction with L-DOPA, extending 
its central bioavailability and allowing a more continuous delivery of L-DOPA to the brain. 
This group includes the monoamine oxidade (MAO)-B inhibitors such as selegiline and 
rasagiline and the Catechol-O-Methyltransferase (COMT) inhibitors entacapone and tolcapone. 
They prevent catabolism of dopamine in the brain and the peripheral metabolism of L-DOPA, 
respectively.  
Amantadine was first introduced as an antiviral agent for the treatment of influenza and 
its anti-parkinsonian effects were discovered serendipitously. Currently, it is the only 
antidyskinetic agent for the treatment of L-DOPA-induced dyskinesias (LID). The exact 
mechanism of action of amantadine is unknown, although it appears to increase dopamine 
release and decrease the reuptake, to inhibit the N-methyl-D-aspartate (NMDA) receptor and to 
have modest anticholinergic activity (Rodnitzky and Narayanan, 2014). 
Anticholinergic agents act by blocking acetylcholine receptors and are the oldest 
treatments still in use for PD. They are useful in alleviation of restring tremor and rigidity. 
Stereotaxic surgery, such as ablation and deep brain stimulation of the globus pallidus 
internus, the thalamus and the subthalamic nucleus is recommended as a treatment for 
medically refractory motor symptoms in PD and patients with LID (Guridi et al., 2008). 
Parkinsonian motor disability tends to improve more in patients with younger age, shorter 
disease duration and less prominent axial symptoms.  
Intrastriatal transplants of fetal mesencephalic tissue has been in the latter years one of 
the most attractive alternatives to treat PD. Clinical trials involving transplantation of 
embryonic mesencephalic dopaminergic neurons have demonstrated that grafted neurons can 
survive long-term (Ma et al., 2010), innervate the denervated striatum (Kordower et al., 1995), 
release dopamine (Piccini et al., 1999) and become functionally integrated into host neuronal 
circuits (Piccini et al., 2000). Unfortunately, they also produce an unknown-caused side effect 
called graft-induced dyskinesia, which has limited this therapeutic approach (Steece-Collier et 
al., 2012). In addition, surviving grafted neurons in patients who died 12 to 16 years after the 
transplant procedure contained pathologic LB-like inclusions (Kordower et al., 2008; Li et al., 
2008), supporting the idea that PD could be a prion-like disorder.  
Genetic therapies are nowadays the new field of intense research in regenerative 
medicine not only for PD but for other neurodegenerative disorders.   
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3.6 Animal models of PD 
There are many different animal models utilized in PD and basal ganglia research. None 
of them directly replicates all the features of human disease with respect to behavioral 
characteristics, brain anatomy, pathology and disease progression, but they have provided 
valuable insight into disease mechanisms and have led to significant advancements in the 
therapeutic treatment. Animal models of PD include pharmacologically-induced models (e.g., 
reserpine and α-methyl-para-tyrosine), neurotoxicant-induced models (e.g., MPTP and 6-
OHDA), genetic models (e.g., alpha-synuclein overexpressing mice and Pitx3 knockout mice) 
and viral models. The 6-OHDA model and a transgenic Pitx3-deleted model have been used for 
the accomplishment of the specific aims of this thesis: 
6-hydroxydopamine (6-OHDA) model. 6-OHDA is a specific catecholaminergic 
neurotoxin structurally analogous to both dopamine and noradrenaline. It has been widely used 
in rodents for basic research on PD since the late sixties when Ungerstedt and colleagues 
performed the first stereotaxic injections into the nigrostriatal pathway (Ungerstedt, 1968). 
Acting as a “false substrate”, 6-OHDA is taken up by dopaminergic and noradrenergic 
transporters into monoaminergic neurons and is accumulated in the cytosol. The mechanisms of 
6-OHDA toxicity are complex and involve different biochemical features including alkylation, 
rapid auto-oxidization that leads to the generation of reactive oxygen species and quinones, and 
impairment of mitochondrial energy production. Dopaminergic cell groups in the midbrain 
exhibit different sensitivities to 6-OHDA. Thus, those in the SNc are the most susceptible 
whereas tuberoinfundibular neurons are almost completely resistant. While clearly useful, the 6
-OHDA model also has some limitations. For instance, LB formation has not been reported in 
this model. 
Since 6-OHDA cannot cross the blood-brain barrier, it must be directly delivered by 
stereotaxic administration into the SN, the median forebrain bundle (MFB) or the striatum. 6-
OHDA lesions in the SN or the MFB induce neuronal degeneration starting within 24 hours. 
When 6-OHDA is injected into the striatum it is retrogradely transported to the dopaminergic 
cell bodies of the SN, where it produces a partial and slow degeneration of dopaminergic 
nigrostriatal neurones lasting 1-3 weeks.  Bilateral administration of 6-OHDA produces a high 
degree of animal morbidity and mortality. Consequently, unilateral intracerebral injections are 
commonly used. Unilateral lesioning results in minimal postoperative mortality and behavioral 
asymmetry. In addition, a non-lesioned side may serve as a control. Approximately 90% 
dopamine depletion in the striatum is required before motor abnormalities are manifested, 
resembling what is found in clinical PD.   
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Genetic model: Aphakia mice. Pitx3-deficient aphakia mouse provides a faithful 
genetic model of neuroanatomical features and motor deficits present in PD (Hwang et al., 
2005; van den Munckhof et al., 2006; Ding et al., 2007). These mice have a spontaneous 
mutation in the transcription factor Pitx3, which is required for the specification and/or survival 
of dopaminergic precursors unique to the SN and not other dopaminergic areas (Nunes et al., 
2003). Lack of Pitx3 in Aphakia mice results in an abnormal development of the A9 dopamine 
neurons and in the selective loss of nigrostriatal dopaminergic projections (Hwang et al., 2003; 
Nunes et al., 2003; Espadas et al., 2012). Therefore, this model resembles a bilateral striatal 
lesion and is also suitable for the study of new therapies as well as the motor complications 
derived from the anti-parkinsonian therapies. 
4.   L-DOPA-INDUCED DYSKINESIA 
L-DOPA-induced dyskinesias are abnormal involuntary movements involving the limbs, 
trunk, or head. They can be severe enough to significantly impair the patient’s life quality and 
can limit the dose of symptomatic therapy, complicating ongoing management of patients with 
advancing PD. Patients with earlier-onset PD tend to be more prone to develop LID than 
patients with later onset (Kumar et al., 2005). LID appears to be a complex set of phenomena; 
this complexity perhaps explains why, despite extensive research, mechanisms underlying LID 
are not yet fully understood. Fortunately, a great number of animal models allow us to further 
investigate both abnormal motor manifestations and molecular alterations in LID. Repeated 
administration of L-DOPA or other dopaminomimetic compounds to MPTP-treated monkeys 
(Bedard et al., 1986; Clarke et al., 1987; Pearce et al., 1995) as well as to 6-OHDA-lesioned 
rats (Cenci et al., 1998; Perier et al., 2003; Marin et al., 2004) and mice (Pavón et al., 2006; 
Darmopil et al., 2009; Smith et al., 2012; Suárez et al., 2014) leads to development of abnormal 
involuntary movements within a few days of treatment resembling “peak-dose-dyskinesias” 
seen in patients. 
4.1 Factors implicated in the generation of LID 
The major factors implicated in the generation of LID seem to be the extent of nigral 
dopaminergic cell loss and the intermittent L-DOPA dosing. 
Dopamine depletion: Progressive degeneration of nigrostriatal neurons and the 
consequent dopamine terminal loss and denervation of striatal neurons have been considered to 
be the pathophysiological basis of dyskinesias (Pavón et al., 2006). Experiments with 6-OHDA
-treated rats revealed that a severe depletion of dopaminergic presynaptic terminals is 
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necessary, while a limited dopaminergic terminal loss is insufficient to develop LID (Papa et 
al., 1994). Moreover, recent work from Pons’ group (2013) indicates that dopamine depletion 
by itself, instead of neuronal degeneration, is the prerequisite for the development of 
dyskinesias (Bezard et al., 2013), supporting previous results found in partially or completely 
denervated striatal areas with 6-OHDA (Pavón et al., 2006). This idea is further supported by 
the fact that patients with TH deficiency due to an autosomal recessive disorder, with intact 
dopamine terminals and striatal innervation, develop dyskinesias after chronic L-DOPA 
treatment (Pons et al., 2013).  
Pulsatile L-DOPA stimulation: Intermittent administration of L-DOPA along with its 
short plasma half-life result in peaks and troughs in plasma levels. In the early stages of PD, the 
administered L-DOPA can be stored and gradually released by the surviving presynaptic 
terminals; however, in more advanced PD, the capacity to buffer fluctuating striatal dopamine 
levels is lost, leading to the appearance of LID. This is supported by the fact that longer acting 
dopamine agonists (Nutt, 2000) or continuous infusion of L-DOPA produce less dyskinesia 
(Jenner, 2008).  
4.2 Changes in basal ganglia motor circuitry in LID 
The combination of extensive destruction of nigrostriatal dopaminergic neurons coupled 
with intermittent L-DOPA dosing can induce plastic changes in basal ganglia function and 
provide a substrate for the development of dyskinesias. It is suggested that the reversed scenario 
than that occurring in PD takes place following L-DOPA administration; thus, D1 and D2 
receptors are overstimulated by L-DOPA, leading to overactivity of the direct output pathway 
and underactivity of the indirect output pathway. This situation induces a reduced activity of the 
STN and GPi/SNr neurons. The net effect of these imbalances would be a reduced inhibition of 
thalamocortical neurons and an overactivation of cortical motor areas, responsible for the 
appearance of abnormal motor activity that characterizes LID (Figure 8).  
4.3 Dopamine D1 receptors hypersensitivity 
Pharmacologic studies implicate both the D1/D5 and D2/D3 receptor families in the 
development of dyskinesias. However, D1-like agonists have a more powerful dyskinetogenic 
effect than D2-like agonists in both PD patients and animal models (Rascol et al., 2001, 2006; 
Holloway et al., 2004). Along with this, D1-like antagonists are more effective at inhibiting 
LID than D2-like antagonists (Taylor et al., 2005; Delfino et al., 2007; Westin et al., 2007). 
Interestingly, previous studies from our laboratory with genetically engineered mice lacking the 
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D1R showed for the first time that D1R is causally linked with behavioral and molecular 
markers of LID (Darmopil et al., 2009). Inactivation of D1R completely blocked LID, while 
D2R knockout mice developed LID as easily as control animals. In addition, it is still possible 
that D3R, which is abnormally expressed in the striatum after chronic L-DOPA administration, 
contributes to LID (Bordet et al., 1997; Bezard et al., 2003). However, D3R antagonists do not 
prevent dyskinetic movements induced by D1R agonists (Kumar et al., 2009; Mela et al., 
2010). 
Figure 8. Simplified diagram of basal ganglia motor circuit in Parkinsonian and dyskinetic state. (A) In 
Parkinsonian state, the lack of dopamine stimulation in the striatum induces reduced activity of the direct pathway 
and increased activity of the indirect pathway, resulting in a final overactivity of the GPi/SNr and a sustained inhi-
bition of the thalamocortical circuits. (B) In LID, dopamine from L-DOPA induces a hyperactivity of the direct 
pathway and an inhibition of indirect pathway. This results in a higher inhibition of the output structure of the BG 
and a reduced inhibition of the thalamocortical loop. Abbreviations: GPe, globus pallidus pars externa; GPi, globus 
pallidus pars interna; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulta; STN, subthalamic 
nucleus. Adapted from Jenner, 2008 and Guridi et al., 2012. 
Enhanced synaptic transmission in LID does not appear to be related to an increase in 
D1R density, but is likely associated with altered redistribution and trafficking of D1R. L-
DOPA-treated Parkinsonian monkeys (Guigoni et al., 2007) and rats (Berthet et al., 2009) 
showed an enhanced expression of D1R at the postsynaptic membrane and in cytoplasmic 
compartments. Moreover, this phenomenon is not limited to D1R, as both NMDA and AMPA 
receptors are also “recruited” at the membrane in dyskinetic monkeys (Hallett et al., 2005; 
Silverdale et al., 2010). These changes are associated with a massive accumulation of the 
synaptic scaffolding protein PSD-95 in the synaptic membrane (Nash et al., 2005). 
Interestingly, PSD-95 has been shown to modulate LID in rats and monkeys by its direct 
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interaction with D1R, since PSD-95 downregulation using lentiviral vectors decreases LID 
(Porras et al., 2012). 
D1R hypersensitivity in 6-OHDA-lesioned rats and PD patients is related to increased 
levels and binding of Gαolf (Corvol et al., 2004). However, results on Gαolf changes following 
L-DOPA treatment are controversial. While L-DOPA treatment has been found to reverse the 
increased Gαolf expression levels seen after striatal denervation in both severe and mild 
dyskinetic rats (Rangel-Barajas et al., 2011), a more recent study from Dr. Hervé’s group 
reports a persistent enhancement of Gαolf in dyskinetic mice as well as a correlation between 
LID and Gαolf levels (Alcacer et al., 2012). However, heterozygous mice for the Gαolf protein 
do not display different dyskinetic behaviour compared to wild type animals (Alcacer et al., 
2012), as would have been expected.  
 In the dopamine-depleted striatum, L-DOPA activates a cAMP-dependent signaling 
cascade via PKA activation (Lebel et al., 2010; Fisone and Bezard, 2011), resulting in 
abnormally increased phosphorylation of DARPP-32 at Thr34 in the MSN of the direct 
pathway (Picconi et al., 2003; Santini et al., 2007, 2010; Bateup et al., 2010) (Figure 9). The 
increased activation of the cAMP/PKA/DARPP-32 pathway observed in dyskinesia induces 
persistent phosphorylation of the AMPA receptor subunit GluR1 at Ser845 (Santini et al., 2007, 
2012) via PP-1 inhibition, enhancing excitatory glutamatergic transmission in D1R-containing 
neurons. AMPA receptor transmission has been seen to be implicated in dyskinesia since an 
AMPA receptor agonist increases LID and an AMPA receptor antagonist reduces it in non-
human primates (Konitsiotis et al., 2000). In agreement, DARPP-32 knockout mice not only 
exhibit reduced LID but also show reduced phosphorylation at Ser845 in GluR1 subunit 
(Santini et al., 2007). 
Induction of the cAMP/PKA/DARPP-32 pathway by L-DOPA also induces the 
activation of the Ras/ERK signaling pathway in the same neurons (Pavón et al., 2006; Santini et 
al., 2007, 2012; Schuster et al., 2008; Fasano et al., 2010). Thus, increased phosphorylation of 
ERK correlates with the intensity of dyskinesias in mice (Pavón et al., 2006; Santini et al., 
2007; Schuster et al., 2008; Lindgren et al., 2010). 
In addition to D1R-pathway, the Ras/ERK cascade can also be activated by the NMDA 
receptor (Hayashi and Huganir, 2004; Ivanov et al., 2006). Increasing NMDA receptor 
activation has been reported following L-DOPA treatment (Chase et al., 2000; Hallett et al., 
2005; Gardoni et al., 2006; Silverdale et al., 2010) and the blockade of NMDA/Ras/ERK 
pathway by lentiviral vectors has been reported to diminish LID in monkeys (Fasano et al., 
2010). However, NMDA receptor antagonists do not modify ERK phosphorylation induced by 
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D1R agonists in the denervated striatum (Gerfen et al., 2002). Thus, these data suggest that 
D1R plays a more important role than the NMDA receptor in the control of ERK cascade 
following chronic L-DOPA treatment, as we suggested (Darmopil et al., 2009). 
Figure 9. Schematic diagram illustrating D1R and NMDAR signaling cascades involved in L-DOPA-
induced dyskinesia. In PD, depletion of dopamine results in increased responsiveness of dopamine D1 receptors. 
Administration of L-DOPA leads to D1R activation and stimulation of adenylyl cyclase through Gαolf protein, 
increasing the production of cAMP and activating PKA. PKA phosphorylates various targets, among which the 
GluR1 subunit of AMPA receptors and DARPP-32. PKA-mediated phosphorylation of GluR1 promotes glutama-
tergic transmission and is intensified by phosphor-DARPP-32 via inhibition of PP-1. In addition, increased PKA/
DARPP-32 signaling as well as stimulation of NMDA receptors lead to activation of Ras/ERK signaling pathway. 
Phospho-ERK translocation to the nucleus results in phosphorylation/activation of CREB and histone H·. This, in 
turn, leads to chromatin rearrangements and transcription of immediate early genes, such as c-Fos and FosB, or 
neuropeptides, such as dynorphin-B. Persistent abnormal activation of theses pathways by L-DOPA appears to be 
involved in long-term changes responsible for dyskinesia.  
ERK activation induced by L-DOPA results in the phosphorylation of the mitogen and 
stress-activated kinase I (MSK-1) and their targets, the transcription factor cAMP response 
element binding protein (CREB) and histone H3. Phosphorylation of both has been found to 
correlate with dyskinesia (Oh et al., 2003; Darmopil et al., 2009). While the signification of 
CREB phosphorylation remains unclear, since downregulation of CREB with an anti-sense 
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oligonucleotide does not affect the ability of L-DOPA to induce dyskinesia (Andersson et al., 
2001), phosphorylation of acetylated histone H3 has been seen to directly correlates with LID 
in mice (Santini et al., 2007; Darmopil et al., 2009; Alcacer et al., 2012) and rats (Cenci and 
Konradi, 2010). Phosphorylation of acetylated histone H3 is involved in chromatin 
decondensation and regulation of nucleosomal response (Cheung et al., 2000; Soloaga et al., 
2003; Harrison and Dexter, 2013). It is therefore likely that the capacity of L-DOPA to enhance 
the levels of phospho-acetylated-histone H3 in direct pathway neurons is involved in the 
changes in gene expression that occur specifically in this neuronal population.  
These events induce transcriptional changes resulting in increased expression of several 
genes that are potentially involved in the development of dyskinesias. Among the various genes 
related to LID, the immediate early gene coding for the transcription factors FosB has received 
particular attention. Increased FosB expression after L-DOPA is directly linked with dyskinesia 
in mice (Pavón et al., 2006; Darmopil et al., 2009) rats (Andersson et al., 1999) and macaques 
(Berton et al., 2009).  Recent studies with viral vectors show that LID appears to be dependent 
mostly on postsynaptic mechanisms mediated by FosB along with its alternatively spliced 
isoforms, collectively named ΔFosB. Recent work from Berton and collaborators has 
demonstrated that viral overexpression of a dominant negative ΔFosB in the striatum of 
dyskinetic macaques dramatically reduced already established LID (Berton et al., 2009). Along 
with these data, viral vector-induced overexpression of ΔFosB exacerbates LID in the rat model 
of PD (Cao et al., 2010). 
Increased levels of FosB/ΔFosB induced by chronic L-DOPA treatment are involved in 
the concomitant up-regulation of mRNA encoding for the opioid neuropeptide dynorphin 
(Andersson et al., 1999). Fos/Jun heterodimers activate a noncanonical AP-1 site in the 
prodynorphin gene (Naranjo et al., 1991), inducing its transcription. Thus, it is consistently 
reported in the literature that L-DOPA induces dynorphin expression in PD patients (Piccini et 
al., 1997), MPTP-treated monkeys (Tamim et al., 2010) and 6-OHDA-treated mice (Darmopil 
et al., 2009). Dynorphin, through presynaptic κ receptors on subthalamic nucleus projections, 
reduces glutamate release in the GPi and SNc. Enhanced opioid transmission is related with a 
reduction of the output inhibitory from GPi, facilitating the appearance of LID (Lavin and 
Garcia-Munoz, 1986; Piccini et al., 1997). These results are strengthened by the fact that 
naloxone (an opioid receptor antagonist) has been found to alleviate L-DOPA-induced 
dyskinesias in PD patients (Sandyk and Snider, 1986) and MPTP-treated monkeys (Klintenberg 
et al., 2002) and tardive dyskinesia in rodents (Stoessl et al., 1993). However, the effects of 
opioid receptor antagonists on LID are contradictory (Samadi et al., 2006) and the precise role 
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played by increased opioid transmission in dyskinesia remains unclear. 
In addition, D1R-mediated activation of adenylyl cyclase/PKA triggers calcium entry 
through voltage-dependent calcium channels (Surmeier et al., 1995) and treatment with the L-
type calcium channel antagonist isradipine diminishes dyskinesias (Schuster et al., 2009), 
further supporting the idea that calcium entry into direct pathway striatal neurons after D1R 
stimulation contributes to LID. 
Altogether, L-DOPA-induced hyperactivation of D1R signaling pathway is directly 
implicated in LID generation. Inhibition of this pathway at different levels is therefore 
considered an attractive target to treat LID in PD patients. However, interventions in this 
signaling cascade may also deregulate a wide range of neuronal functions. Based on these 
accounts, it seems logical to propose that interventions downstream from this pathway would 
have a clear advantage in finding a suitable target for LID. 
5.  DREAM protein 
The downstream regulatory element antagonist modulator (DREAM) is a calcium 
binding protein which belongs to the Neuronal Calcium Sensor (NCS) protein family 
(Burgoyne and Weiss, 2001). It was first cloned by Dr. Naranjo’s group in the search for 
nuclear proteins that regulate the transcription of human prodynorphin gene (Carrión et al., 
1999). DREAM is also known as calsenilin, as it binds presenilin and may promote 
amyloidogenesis (Buxbaum et al., 1998; Lilliehook et al., 2003) and KChIP3, one of the four 
members of the voltage gated Potassium Channel Interacting Protein subfamily of NCS (An et 
al., 2000), which interact with Kv4 potassium channels to regulate their membrane expression 
and gating. 
The mouse DREAM cDNA shares an overall identity of 85% with its human 
counterpart and, at the amino acid level, mouse and human proteins are 91% identical 
(Spreafico et al., 2001). The full length DREAM protein consists of 256 amino acids with a 
predicted molecular mass of around 32 kDa. It contains four EF-hands of which three (II, III 
and IV) bind calcium while the first one is a non-canonical and not functional EF-hand. 
DREAM protein can also interact with other proteins through two leucine-charged residue rich 
domains (LCD) located in positions 47 and 155. Binding of DREAM to calcium or to proteins 
regulates its physiological functions. 
DREAM is expressed in all embryonic stages and in adult mice in the central and 
peripheral nervous system and in other tissues such as heart, thymus, gonads and thyroid. RT-
PCR and in situ hybridization experiments (Spreafico et al., 2001; Xiong et al., 2004) showed a 
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diffuse expression in almost all brain regions.  
DREAM plays different roles depending on its subcellular localization. In the nucleus, 
DREAM acts as a mediator of calcium- and cAMP-dependent transcriptional responses (Ledo 
et al., 2000a) and regulates activity-dependent gene expression through direct interaction with 
regulatory sites in the DNA (Carrión et al., 1999). The initial downstream regulatory element 
(DRE) sequence was first found in the promoter region of the human prodynorphin gene 
(Carrión et al., 1998). It was defined as the element responsible for its basal and induced 
expression and was localized within the first exon in the 5’ untranslated region of the gene, only 
functional when located downstream from the TATA box (i.e., initiation transcription site). In 
basal conditions, DREAM binds as a tetramer to the DRE site in the promoter of target genes, 
repressing their transcription. The protein is also capable of binding to the DRE sequence as a 
monomer or as a dimer, but with lower affinity.  
DREAM-mediated repression of target genes can be reversed upon cellular stimulation 
by two different mechanisms. Following an increase in intracellular calcium, DREAM detaches 
from DNA allowing transcription (Carrión et al., 1999) (Figure 10A). Previous works have 
demonstrated that mutation of two key amino acids within any of the three functional EF-hands 
results in mutated forms of DREAM insensitive to calcium that stay bound to DRE sites, 
blocking the transcription process (Savignac et al., 2005).  
In addition to calcium and independently of it, transcriptional repression can be reversed 
by the direct interaction between DREAM and the nucleoproteins α and ε CREM, the cAMP 
responsive element modulators (Ledo et al., 2000b) (Figure 10B). The phosphorylation of α and 
ε CREM by PKA strengthens the interaction between both proteins but is not required for the 
detachment of DREAM from the DRE sites. Site-directed mutagenesis of one residue in any of 
the LCD of DREAM blocks the interaction with CREM and produces DREAM mutants 
insensitive to PKA-dependant derepression (Ledo et al., 2000b).  
Besides the direct repression of transcription by binding to DRE sites in the DNA, 
DREAM can also regulate CRE-mediated transcription (Ledo et al., 2002). In absence of 
calcium, DREAM binds to CREB, avoiding the CREB-CBP interaction and blocking CRE-
mediated transcription. Upon calcium stimulation, DREAM detaches from CREB, allowing 
transcription. Thus, DREAM represents a point of cross talk between cAMP and calcium 
signaling pathways in the nucleus.    
The non-transcriptional effects of DREAM have been shown to regulate cell function 
and synaptic activity, mostly through a variety of specific protein-protein interactions outside 
the nucleus (Rivas et al., 2011). The list of target proteins includes cationic channels (An et al., 
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2000), membrane receptors such as the NR1a C terminus subunit of the NMDA receptor (Rivas 
et al., 2009; Zhang et al., 2010) and membrane docking proteins such as PSD-95 (Wu et al., 
2010), thus inhibiting NMDA receptor activity and its surface expression.  
Figure 10. Repression of target genes by DREAM can be reversed by calcium and CREM. In the nucleus, 
DREAM represses gene expression through direct interaction with DRE sites in the DNA. (A) Following an in-
crease in intracellular calcium, DREAM binds to calcium and detaches from DNA, allowing transcription of target 
genes. (B) In addition to calcium and independently of it, transcriptional repression by DREAM can be reversed by 
the direct interaction between DREAM and the nucleoproteins α and ε CREM.  
Based on these observations and on the previous data demonstrating a close association 
between LID and overexpression of FosB and dynorphin-B (Pavón et al., 2006; Darmopil et al., 
2009), we propose that DREAM, located downstream of D1R-dependent cAMP/PKA 
activation, plays an important role in the cascade of molecular events leading to LID. If this is 
so, DREAM could provide a site for intervention to improve the efficacy of L-DOPA treatment 
while preventing the upregulation of target genes associated with dyskinesia. 
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HYPOTHESES  
 
1. Dopamine differentially regulates striatal Gαolf expression through D1 and D2 receptor 
signaling. 
2. DREAM protein activation diminishes L-DOPA-induced dyskinesias, decreasing D1R-
dependent signaling, by transcriptional and non transcriptional mechanisms. 
 
GENERAL OBJECTIVES 
1. To elucidate the role of dopamine-dependent signaling in striatal Gαolf expression. 
2. To determine the role of DREAM protein in L-DOPA-induced dyskinesias and in the 
associated molecular changes in hemiparkinsonian mice. 
 
SPECIFIC OBJECTIVES 
1.1   To establish the role of dopamine in striatal Gαolf expression using 6-OHDA-lesioned 
mice or aphakia mice.   
1.2   To investigate the role of dopamine receptors in striatal Gαolf expression using D1R and 
D2R knockout mice. 
2.1  To analyze the impact of DREAM genetic modulation on L-DOPA-induced dyskinesias. 
2.2  To examine whether DREAM activation diminishes L-DOPA-induced dyskinesias by 
decreasing cAMP-dependent transcription of FosB and dynorphin-B in striatal neurons.  

Materials & Methods 
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1. ANIMALS 
During the development of this thesis, adult mice of 3-6 months of age and 25-30 g 
weight at the beginning of the experiments were used (Cajal Institute, CSIC, Madrid, Spain). 
Experiments for the study of Gαolf protein expression were performed in mice lacking D1 
receptor (D1R-/-) (Moratalla et al., 1996b; Centonze et al., 2003; Granado et al., 2008b; Espadas 
et al., 2012), D2 receptor (D2R-/-) (Kelly et al., 1997; Darmopil et al., 2009; Granado et al., 
2011; Murer and Moratalla, 2011; Espadas et al., 2012) and in Pitx3-deficient aphakia mice 
(Pitx3-/-) described previously by Smidt and colleagues (2004). 
The study of the DREAM protein was carried out in transgenic mice expressing a 
dominant active mutant DREAM (daDREAM) (Gomez-Villafuertes et al., 2005; Savignac et 
al., 2005) or in DREAM-/- deficient mice (Cheng et al., 2002; Cebolla et al., 2008) provided by 
Dr. Jose Ramón Naranjo from Centro Nacional de Biotecnología (CNB, CSIC, Madrid). In the 
daDREAM transgenic mice, expression of the transgene, a bi-cistronic construct including the 
daDREAM mutant, an IRES sequence and the lacZ reporter, was driven by the calcium/
calmodulin-dependen protein kinase type II (CaMK-II) alpha promoter (Mayford et al., 1996). 
The transgenic line (JN26) used in this study has a telencepahlic-specific expression with high 
levels of transgene expression in the striatum. Bacterial artificial chromosome (BAC)-
transgenic D1R-tomato mice (Suárez et al., 2014) were used to study DREAM striatal 
localization. 
Genetically modified animals and wild-type controls were maintained in a C57-BL/6 
background and derived from mating the corresponding heterozygous mice. Genotyping was 
performed by PCR analysis.  
Mice were housed in standard Plexiglas cages with maximally 6 animals/cage with ad 
libitum access to food and water. The environmental conditions were strictly controlled, with a 
12 hours light/dark cycle, temperature of 22°C±2 and 44%±2 humidity.  
Experimental protocols were designed in order to minimize the number of mice used in 
these studies as well as their discomfort. All animal procedures followed guidelines from 
European Union Council Directive (86/609/European Economic Community) and experimental 
protocols were approved by the CSIC Ethics Committee. 
2.   DOPAMINE DENERVATING LESIONS 
Insomuch as 6-OHDA produces selective degeneration of catecholamine neurons, mice 
received an intraperitoneal injection of 20 mg/kg of the noradrenaline reuptake inhibitor 
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desipramine hydrochloride (Sigma-Aldrich, St. Louis, Missouri, USA) thirty minutes before 
lesion (Breese and Traylor, 1971) in order to protect the noradrenergic neurons from 6-OHDA 
neurotoxicity and to achieve specific dopaminergic lesions. 
Figure 11. Stereotaxic instrument to 6-OHDA lesion procedure. Mice were mounted on a stereotaxic frame 
equipped with a mouse adaptor and maintained under isofluorane anesthesia. A hole was drill on the skull and 6-
OHDA was injected using a Hamilton syringe connected to a pump. 
Animals were anesthetized with 2% v/v isoflurane at a flow rate of 0.4-0.6 l/min 
oxygen, placed in a stereotaxic frame equipped with a mouse-adaptor (Kopf Instruments, 
Tujunga, CA, USA) and kept anesthetized using 1-1.5% v/v isoflurane (Figure 11). Antibiotic 
cream or vaseline were used to protect the eyes from drying during surgery. Using a 10 μl 
Hamilton syringe (Hamilton, Bonaduz, Switzerland), animals received unilateral stereotaxic 
injections (2 x 2 µl) of 6-OHDA-HBr (5 µg/µl, 20 mM, containing 0.02 % ascorbic acid; Sigma
-Aldrich) at the following coordinates (mm from bregma and dural surface; cf. Paxinos and 
Franklin 2004): AP = +0.65, L = -2 and V = -4 and -3.5, targeting the left dorsolateral striatum. 
For each deposit, toxin was infused at 0.5 μl/min flow rate and the needle was left in place for 
10 minutes before being slowly removed, in order to favor 6-OHDA diffusion and to avoid 
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reflux along the track. After the injection, the skin was sutured and the animals, once removed 
from the stereotaxic instrument, were placed in a clean cage on a heating pad until complete 
recovery from anesthesia. During the days following surgery, mice received subcutaneous 
injections of saline solution to prevent dehydration, as well as supplementary food and hand-
feeding when necessary.  
3.   L-DOPA TREATMENT 
All drugs used in these studies were dissolved in saline solution (0.9% w/v NaCl) and 
intraperitoneally (i.p.) administrated in a final volume of 10 ml/kg body weight.  
Mice were left to recover 3 weeks after the lesion and then were submitted to L-DOPA 
methyl ester (Sigma-Aldrich) treatment during the following 3 weeks. Animals received a daily 
intraperitoneal injection of 25 mg/kg of L-DOPA 20 minutes after benserazide hydrochloride 
(10 mg/kg body weight, Sigma-Aldrich), a peripheral blocker of the DOPA decarboxylase. This 
protocol of administration has been previously seen to induce a gradual development of 
dyskinetic-like movements described in 6-OHDA lesioned rats (Winkler et al., 2002) and mice 
(Lundblad et al., 2004; Pavón et al., 2006).  
4.   BEHAVIORAL ANALYSIS 
4.1 Locomotor activity 
We carried out spontaneous locomotor activity tests in basal conditions (i.e. before 6-
OHDA lesion) to rule out any motor impairment in our DREAM mutant mice that could 
interfere with L-DOPA behavioral studies. To achieve this goal, we analyzed horizontal and 
vertical activity as well as total distance traveled during 60 minutes using a multicage activity 
monitoring system (AccuScan Instruments, Inc.; Versamax Software) with a set of 8 individual 
cages measuring 20 x 20 x 28 cm. Horizontal movements were detected by 2 arrays of 16 
infrared beams spaced 2.5 cm, whereas a third array positioned 4 cm above the floor detected 
vertical movements. The software allowed a distinction to be made between repetitive 
interruptions of the same photobeam and interruptions of adjacent photobeams. Thus, 
horizontal and vertical activities were measured as the total number of beam interruptions that 
occurred in the horizontal and the vertical sensor respectively during the sample period while 
the total distance indicates the distance traveled in centimeters and is used as an index of 
ambulatory activity.  
Mice were habituated to the cages in 1 hour sessions for 2 days to avoid exploratory 
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behavior due to the novel environment. The third day, animals were recorded for 1 hour during 
the light phase of the light-dark cycle. 
4.2 Motor coordination 
To further study motor function in our mutant mice, animals were submitted to the 
rotarod test (Ugo Basile, Varese, Italia). The rotarod is a beam that can rotate at a fixed or an 
accelerated speed. Mice are placed on the beam and their latency to fall off the rod provides a 
measurement of their motor coordination. To test our animals we used an accelerating version 
of the test, with increasing speed from 4 to 40 rpm over a 5 minutes period.  
Before the test, animals were habituated to the rotarod for 30 seconds in the immobile 
rod followed for 1 minute in a low fixed speed. If the mouse fell from the rotarod during the 
training session, it was placed back. Then the performance of the mice was tested in 6 
consecutive trials 20 minutes apart (Figure 12A).  
This test was also used to measure the antiparkinsonian effect of the L-DOPA. To 
achieve this goal, mice were tested before 6-OHDA (naïve), 3 weeks after lesion (parkinsonian) 
and during L-DOPA treatment (dyskinetic) on day 9, 24 hours after the last L-DOPA injection 
in order to avoid exhaustion and the peak dyskinesia, which could interfere with the 
performance of the test. It is noteworthy that the parkinsonian condition should be measured 
when the animals are completely recovered from the surgical intervention and when the plastic 
changes caused by dopamine cell degeneration have stabilized. 
Figure 12. Rotarod and cylinder tests. (A) The rotarod test is used to evaluate motor coordination. Mice are 
placed in the rotating rod and their latency to fall off the rod provides a measurement of their motor coordination.
(B) The cylinder test is frequently used to evaluate forelimb akinesia and asymmetry in unilateral rodent models of 
PD. Mice are placed in a glass cylinder and the number of wall contacts performed independently with the left and 
the right forepaw are counted per session. 
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4.3 Cylinder test 
The cylinder test is frequently used to evaluate forelimb akinesia and asymmetry in 
unilateral rodent models of PD (Francardo et al., 2011; Espadas et al., 2012). This test takes 
advantage of the exploratory response that is typical for rodents. A rodent placed in a novel 
environment will explore the enclosing walls by standing on its hindlimbs and using its 
forelimbs to support the body against a nearby wall. A measure of limb use asymmetry is 
obtaining by counting the number of supporting wall contacts that the rodent executes 
independently with each paw. A unilateral 6-OHDA lesion will cause a notable reduction in the 
spontaneous use of the contralateral paw, which will be restored by an effective L-DOPA 
therapy.  
For the evaluations, mice were placed individually inside a 10 cm diameter glass 
cylinder, which was located in front of a mirror, in order to be able to view the mice from all 
the angles, and videotaped for 3 minutes (Figure 12B). No habituation of the animals to the 
testing cylinder was allowed before videorecording them. The number of wall contacts 
performed independently with the left and the right forepaw were counted per session. Only 
wall contacts where the animal supported body-weight on the paw with extended digits were 
counted whereas simultaneous ipsilateral and contralateral forelimb touches were excluded 
from the count. Forelimb asymmetry was expressed as percentage of contra-lateral touches ± 
SEM over the total number of wall contacts. 
Cylinder test was performed before the 6-OHDA lesion (naïve), 3 weeks after lesion 
(parkinsonian) and on day 17 of the chronic L-DOPA treatment (dyskinetic), 140 minutes after 
L-DOPA injection to avoid dyskinetic symptoms.  
5.   L-DOPA-INDUCED DYSKINESIA 
L-DOPA-induced dyskinesias were evaluated twice a week for 3 weeks, 40 minutes 
after L-DOPA administration using a 0-4 severity scale as previously described (Pavón et al., 
2006). Mice were placed individually into a 10 cm diameter glass cylinder and videotaped for 4 
minutes. The time course of L-DOPA response for each genotype was evaluated on day 20 of 
chronic treatment, for 1 minute every 20 minutes during 160 minutes post-L-DOPA injection. 
As in the rat (Cenci et al., 1998; Winkler et al., 2002) and in the mice model (Lundblad 
et al., 2004; Pavón et al., 2006), we have separately evaluated four subtypes of dyskinetic 
symptoms according to their topographical distribution (Figure 13):  
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 Locomotive dyskinesia: Circular asymmetric locomotion, towards the contralateral side to 
the lesion.  
 Axial dystonia: Deviation or torsion of the head, neck and trunk towards the contralateral 
side, leading to a loss of the orthostatic equilibrium, with a choreiform twisting character. 
 Limb dyskinesia: Jerky movements of the forelimb contralateral to the lesion with choreic 
or ballistic nature.  
 Orofacial dyskinesia: Jaw movements more pronounced toward the contralateral side, 
sometimes including tongue protusion. They are usually complicated by self-mutilative 
biting of the fur and the skin on the forelimb contralateral to the lesion. 
To assess dyskinesia’s severity we have used the scale developed previously in rat 
(Winkler et al., 2002) and adapted to mouse model (Pavón et al., 2006). 
Severity rating scale 
0: Absent, no dyskinesia. 
1: Occasional dyskinetic symptoms, present during less than half of the observation time. 
2: Frequent dyskinetic symptoms, present during more than half of the observation time. 
3: Continuous dyskinetic symptoms during all the observation time but suppressible by external 
stimuli, i.e., sudden, noisy opening of the cage or a slow blow to the glass cylinder. 
4: Continuous dyskinetic symptoms during all the observation time not suppressible by external 
stimuli.  
Upon uncertainly between two consecutive grades of the scale, the corresponding half 
score was given.  
6.   IMMUNOHISTOCHEMISTRY 
Following behavioral analysis, mice were sacrificed 3 weeks after 6-OHDA lesion or 1 
hour after last L-DOPA administration, by an overdose of pentobarbital (Laboratorios Normon, 
Madrid, Spain). They were injected intracardially with 0.5 ml of 1 % heparin (Rovi, Madrid, 
Spain) and perfused with 10 ml of saline solution, followed by 60 ml of 4 % paraformaldehyde 
in phosphate buffer pH 7.4. The brains were post-fixed for 24 hours and were then transferred 
to a 0.1 M phosphate buffer solution (PBS) containing 0.02 % sodium azide for storage at 4ªC. 
Brains were further immersed in 3 % agarose and they were cut in 30-µm-thick coronal sections 
using a vibratome (Leica, Wetzlar, Germany). They were stored at 4ºC in 0.1 M PBS containing 
0.02 % sodium azide, ortavanadate 1mM and NaF 5mM, to avoid phosphoproteins degradation.  
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6.1 Single antigen DAB immunostaining 
Immunostaining was carried out in free-floating sections using a standard avidin-biotin 
immunocytochemical protocol (Rivera et al., 2002b; Grande et al., 2004). Endogenous 
peroxidase activity was quenched by incubation for 10 min in 0.1 M PBS containing 0.2% 
Triton X-100 (PBS-TX) with 3 % hydrogen peroxide. Non-specific binding sites were blocked 
for 60-90 min with 5-10 % of goat serum in PBS-TX followed by incubation at 4ºC with the 
indicated primary antibodies (see Table I). After incubation with the primary antibody, the 
sections were washed and incubated with the goat anti-rabbit biotinylated secondary antibody 
Figure 13. Dyskinetic symptoms induced by chronic L-DOPA treatment in hemiparkinsonian mice. Time-
lapse video photographs illustrating representative dyskinetic symptoms 30 minutes after 25 mg/kg L-DOPA ad-
ministration. (A) Orofacial dyskinesia, expressed as tongue protrusion and vacuous chewing movements. (B) Limb 
dyskinesia, seen as jerks on the side contralateral to the lesion. (C) Locomotive dyskinesia, manifested as a ten-
dency to turn toward the side contralateral to the lesion. (D) Axial dystonia of the trunk toward the contralateral 
side. Adapted from Pavón et al., 2006. 
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(1:500, Vector Labs, Burlingame, CA, USA) for 1-2 h at room temperature. After washing, the 
sections were incubated with streptavidin (Zymed, San Francisco, CA, USA) for 1 h and 
antibody staining was developed using only DAB (Sigma-Aldrich) for TH, calbindin, Gαolf, 
DREAM and P-AcH3 or DAB with addition of nickel to intensify the reaction in case of MOR-
1, FosB and dynorphin-B immunohistochemistry. After developing the reaction, stained 
sections were mounted, dried, dehydrated and cover slipped with Permount mounting medium 
(Fisher Chemicals, Fair Lawn, NJ, USA) and examined using a light microscope (Leica, 
Heidelberg, Germany). 
Primary antibody  Dilution Incubation Brand 
Rabbit anti-calbindin Polyclonal 1:1500 1 ON, 4ºC Millipore 
Rabbit anti-DREAM Polyclonal 1:250 1 ON, 4ºC Santa Cruz Int 
Rabbit anti-DynB Polyclonal 1:500 3 ON, 4ºC Dr. Watson Lab 
Rabbit anti-FosB Polyclonal 1:7500 3 ON, 4ºC Santa Cruz Int 
Rabbit anti-Gαolf Polyclonal 1:4000 1 ON, 4ºC Dr. Hervé Lab 
Goat anti-mCherry Polyclonal 1:500 1 ON, 4ºC Acris Antibodies 
Rabbit anti-MOR-1 Polyclonal 1:10000 3 ON, 4ºC Millipore 
Rabbit anti-P-AcH3 Polyclonal 1:1500 2 ON, 4ºC Millipore 
Polyclonal 1:1000 1 ON, 4ºC Millipore Rabbit anti-TH 
Table I. Primary antibodies used for the immunohistochemical studies. ON: Over-night.   
6.2 Fluorescent labelling immunostaining 
To identify DREAM striatal localization in direct and indirect projection neurons, we 
used a rabbit DREAM antiserum (1:250, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
a goat mCherry antiserum (1:500, Acris Antibodies, San Diego, CA, USA) which labeled the 
tomato protein expressed by the direct pathway neurons in our (BAC)-transgenic D1R-tomato 
mice. The aim of immunolabing the tomato protein is to extend the half-life of the red 
fluorescence when examined by laser confocal microscopy, as the fluorescence of the native 
fluorophore is rapidly extinguished under laser excitation. 
Free-floating sections were incubated for 1 hour with 10% of donkey serum in PBS-TX 
followed by an overnight incubation at 4ºC with DREAM antibody diluted in 0.1 M PBS-TX 
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with 2 % donkey serum. After incubation with the primary antibody, the sections were washed 
and incubated with the donkey anti-rabbit Alexa 488-conjugated antibody (1:500, Molecular 
Probes, Invitrogen, Eugene, OR, USA) for 4 hours at room temperature. In order to protect 
DREAM immunostaining, sections were incubated with 4 % paraformaldehyde in phosphate 
buffer pH 7.4 for 10 minutes at room temperature before being blocked again with 10% of 
donkey serum and incubated overnight with mCherry antiserum. Donkey anti-goat Alexa 594-
conjugated antibody (1:500, Molecular Probes) was used to detect mCherry. Finally, sections 
were incubated with Hoechst (1 µg/ml, Sigma-Aldrich) for 10 minutes at room temperature to 
stain the nuclei.  
Sections were mounted in fluorescent mounting medium (DABCO, Fluka, Buchs, 
Switzerland), coverslipped, kept in the dark at 4 °C until they were examined by laser confocal 
microscopy (Leica). The specific immunofluorescence of the Alexa 488 or Alexa 568/594 
fluorophores was visualized by excitation at 488 nm or 568 nm, respectively. 
7.  QUANTITATIVE REAL-TIME PCR 
Animals were killed by decapitation 1 hour after last L-DOPA administration. Tissue 
samples from striatum and substantia nigra were stored at -80ºC immediately after obtaining. 
RNA was extracted and purified with the QuickGene RNA tissue kit S II (RT-S2) and the QG-
Mini80 system device (Fujifilm). RNA quality was determined using a NanoDrop. Reverse 
transcription was performed with 50 ng/µl of RNA using iScript Reverse Transcription 
Supermix for RT-qPCR kit (BioRad). Quantitative real-time PCR was performed with 25 ng of 
cDNA and 1 µl of Taqman probes (Applied Biosystems, CA, USA) to detect TH, FosB, PDyn, 
DREAM, Gαolf and GAPDH and 18S as reference genes, using a 7000 Fast Real-Time PCR 
system device and TaqMan universal PCR Master Mix (Applied Biosystems). Expression of 
target genes was normalized using the GAPDH or 18S expression and calculated using the 
comparative cycle threshold method, 2-ΔΔCt, where ΔΔCt = (Ct,target gene - Ct,reference gene)treated - 
(Ct,target gene - Ct,reference gene)untreated (Livak et al., 2001). 
8.  WESTERN BLOTTING 
Animals were sacrificed by decapitation 30 min after the last L-DOPA injection. Striatal 
tissue was dissected, homogenized on ice in 150 µl of lysis buffer [Hepes pH 7.4, 50 mM; NA 
Pirophsphate 10 mM; Triton 1%; Glycerol 10%; EDTA 2 mM; Ortovanadate 2 mM; NaF 100 
mM; protease inhibitor cocktail (Roche Applied Science)]. The homogenates were cleared by 
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centrifugation for 30 min at 4ºC and 10,000 g. Supernatants were placed into new tubes and the 
final protein concentration was quantified by the Bradford method (BioRad, Madrid, Spain).  
Western blot analyses were carried out with 20 µg of protein, separated on SDS/7.5% 
PAGE by constant amperage and 100V electrophoresis. Proteins transfer was done onto 0.45 
µm polyvinylidene fluoride membranes (Pall Corporation, Pensacola, Florida, USA) with a 
semy-dry transfer system (Trans-Blot Turbo, Bio-Rad) at 100V and 2.5 A for 30 minutes. After 
rinsing membranes briefly in water and T-TBS (Tris 20 mM pH 7.4; NaCl 137 mM; 
Ortovanadate 1 mM; NaF 5 mM; Tween 1%), they were blocked with 5% non-fat dry milk (TH 
and β-actin detection) or with 10% BSA (P-GluR1 immunoblot) in T-TBS for 1-2 hours and 
incubated overnight at 4ºC with the indicated antibodies. Immunodetection was performed with 
primary monoclonal antisera against phospho-Ser845-GluR1 (1:7500; Millipore) and β-actin 
(1:50000; Sigma-Aldrich) as loading control. Antibody against TH (1:4000; Millipore) was 
used to prove the 6-OHDA lesion. Blots were incubated for 1-2 hours at room temperature with 
a peroxidase-conjugated secondary antibody (Vector Labs, Burlingame, CA, USA), developed 
by enhanced chemiluminiscence (ECL-plus, GE Healthcare, UK) and quantified by 
densitometric scanning of films (Quantity One, BioRad). 
9.  QUANTIFICATIONS 
9.1 Striatal lesions 
Measurement of the extent of the dopaminergic lesion was performed using Neurolucida 
software (Microbrightfield Bioscience, Williston, Vermont, USA). The borders of the areas of 
striatum with complete loss of TH-immunoreactive fibers were outlined from a live image with 
a 4x objective using 7-9 serial rostrocaudal sections per animal. Area of interest was calculated 
by determining the coordinates of each point around the contour and summing the contained 
area by the software. 
9.2 Nuclear density 
Quantification of FosB and P-AcH3 immunoreactivity was carried by nucleus count 
(Darmopil et al., 2009), with the aid of an image analysis system (AIS, Imaging Research Inc., 
Linton, England). For both lesioned and unlesioned striatal sides, number of immunolabelled 
nuclei was determined in 4-6 animals per group using 5 serial rostrocaudal sections per animal 
and 3 counting frames (dorsal, dorsolateral and lateral) per section (0.091 mm2 each frame). 
Images were digitized with Leica microscope under 40x lens. Before counting, images were 
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thresholded at a standardized gray-scale level, empirically determined by 2 different observers 
to allow detection of stained nuclei from low to high intensity, with suppression of very lightly 
stained nuclei. The data are presented as number of stained nuclei per mm2 (mean ± standard 
error) in the lesioned and unlesioned striatum.  
9.3 Proportional stained area 
Quantification of dynorphin-B and Gαolf expression was carried out using an image 
analysis system (AIS, Imaging Research, Linton, UK) as in Granado et al., 2008c and Ares-
Santos et al., 2012. Images were digitized using a light microscope (Leica, Heidelberg, 
Germany) under 4x lens. The proportional Gαolf-stained area was determined in 4–6 animals 
per group using 5-7 serial rostrocaudal sections per animal. Images were thresholded at a 
standardized gray-scale level and the area of staining in the striatum was quantified. Data are 
presented as the proportional area (total positive area/scan area). 
10.   STATISTICAL ANALYSIS 
Basal locomotor activity and dyskinetic behavioral data were analyzed using two-way 
ANOVA with repeated measures using genotype and time/trial as variables, followed by 
planned comparisons (a priori analysis, Newman-Keuls post hoc test). Rotarod and cylinder 
tests significances were estimated by two-way ANOVA with genotype and trial/treatment as 
variables, followed by Newman-Keuls post hoc test. Quantifications of immunolabeling were 
analyzed by two-way ANOVA with genotype and lesion as between-subject variables, followed 
by Student-Newman-Keuls post hoc test. The extent of the dopaminergic lesion and the mRNA 
expression were analyzed by one-way ANOVA.  
Data are expressed as mean ± standard error of mean (SEM). Differences were 
considered statistically significant at p<0.05. 
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1. GαOLF EXPRESSION 
In rodents, the olfactory type G-protein α subunit (Gαolf protein) couples striatal dopa-
mine D1 receptors and adenosine A2a receptors to adenylyl cyclase, mediating the cAMP pro-
duction. Alterations in the cAMP-signaling pathway have been reported to directly lead to L-
DOPA-induced dyskinesias (Pavón et al., 2006; Darmopil et al., 2009; Lebel et al., 2010; 
Fisone and Bezard, 2011; Alcacer et al., 2012; Santini et al., 2012). However, despite the pro-
gress made in the last decades, changes in Gαolf expression following striatal dopamine deple-
tion and L-DOPA treatment are not yet fully established. The experimental results presented 
here aim to shed light to the Gαolf regulation by dopamine, as the key protein of cAMP-
dependent signaling after D1R activation. 
1.1. Pattern of Gαolf expression in basal conditions 
We carried out immunohistochemical studies of serial adjacent rostrocaudal sections of 
adult mice, in naïve conditions, in order to test the specificity of our antibody and to confirm 
the Gaolf expression pattern described before (Sako et al., 2010). 
Figure 14. Striatal localization of Gαolf in adult mice. Representative photomicrographs of serial adjacent ros-
trocaudal brain sections from adult mice immunostained for MOR-1, Gαolf and calbindin. Right panels show an 
example of striosomes. Notice the higher expression of Gαolf in the striosomes compared to the matrix area. Bars 
indicate 500 µm and 250 µm.  
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As expected, Gαolf protein showed a patchy distribution all along the rostrocaudal axis 
(Figure 14). To confirm that the patches of higher Gαolf expression corresponded with the loca-
tion of striosomes, adjacent brain sections were immunostained for MOR-1 (μ opioid receptor-
1), a marker for striosomes (Breuer et al., 2005; Lawhorn et al., 2009; Tajima and Fukuda, 
2013), and for the calcium-binding protein calbindin D28K, a marker for the large matrix com-
partment surrounding the striosomes (Davis and Puhl, 2011; Watabe-Uchida et al., 2012). This 
strategy permitted direct comparisons of the Gαolf-positive patches with the striosomes labeled 
with MOR-1 and with the matrix labeled with calbindin. The zones of heightened Gαolf signal 
corresponded with the MOR-1-enriched areas and with the calbindin-poor areas, evidencing the 
compartmentalized distribution of the Gαolf protein in the adult mice striatum. 
1.2.  Regulation of Gαolf expression by dopamine: Parkinsonian and dyskinetic mice 
To examine the role of dopamine in Gαolf expression, we used a mouse model of ni-
grostriatal dopaminergic denervation with a robust reduction of dopamine levels in the striatum, 
resembling the loss of dopamine found in the putamen of patients with PD. Wild type mice 
were submitted to unilateral 6-OHDA striatal lesions to obtain the hemiparkinsonian model. 
Three weeks after the lesion, when the plastic changes caused by dopaminergic cell degenera-
tion were stabilized, striatal Gαolf expression was investigated by immunohistochemistry. Stri-
atal Gαolf levels in wild type animals were higher in Parkinsonian than in naïve condition 
(Figure 15A), in agreement with previous results (Hervé et al., 1993; Marcotte et al., 1994; 
Corvol et al., 2004) obtained by western blot experiments in rodents. Quantification analysis 
carried out by optical density showed a 15 % increase in the lesioned striatum compared to the 
unlesioned one (Figure 15B). Interestingly, the striosomal pattern described for the naïve wild 
type animals was not evident in the dopamine-depleted striatum ipsilateral to 6-OHDA injec-
tions. Both the increase in Gαolf expression and the loss of pattern suggest that dopamine de-
pletion induces an increase of Gαolf expression levels in the matrix compartment reaching 
those of the striosomes.  
Because the increase in Gαolf levels could be induced by the lack of dopamine stimula-
tion, we studied the effect of exogenous dopamine replacement on Gαolf expression. To 
achieve this goal, we treated hemiparkinsonian wild type mice chronically with 25 mg/kg of L-
DOPA. We have demonstrated that this protocol of administration besides inducing severe L-
DOPA-induced dyskinesia in wild type animals (Pavón et al., 2006; Darmopil et al., 2009; 
Suárez et al., 2014), temporarily increases striatal dopamine levels (Espadas et al., 2012). 
Treatment with 25 mg/kg of L-DOPA for 3 weeks in Parkinsonian mice reversed the 
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increase in Gαolf expression, which returned to naïve/control levels (Figure 15A,B). Moreover, 
image analysis of microscopic photographs indicates that this down-regulation of Gαolf may 
take part mainly in the matrix, as some Gαolf striosomes can be observed in the ipsilateral stria-
tum of dyskinetic mice. 
However, these changes in protein levels were not associated with similar variations in 
Gαolf mRNA. RT-qPCR experiments showed that dopamine depletion did not modify Gαolf 
mRNA regardless of the increase in the protein levels found in the hemiparkinsonian mice. In-
triguingly, L-DOPA treatment induced a 50% increase of Gαolf mRNA levels, in sharp contrast 
to its effect in the protein concentrations (Figure 15C). 
Figure 15. Gαolf expression in the striatum of Parkinsonian and dykinetic mice. (A) Representative photomi-
crographs of striatal rostrocaudal sections from adult mice in naïve, Parkinsonian and dyskinetic condition, immu-
nostained for TH and Gαolf. Histograms show quantifications of (B) Gαolf protein measured as the proportional 
stained area of Gαolf-immunoreactivity and (C) Gαolf mRNA expressed as normalized mRNA levels to GAPDH. 
Data (mean ± SEM) were analyzed by one-way ANOVA followed by Newman-Keuls test. *p<0.05, **p<0.001 vs 
saline. Bar = 500 µm. n=5-7.  
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1.3.  Genetic inactivation of Pitx3 increases Gαolf expression and induces the loss of 
striosomal pattern, while L-DOPA treatment restores both 
In order to control for the effect of chemical lesions in our dopamine depletion experi-
ments, we analyzed Gαolf expression in the striatum of Pitx3-deficient aphakia mice, a genetic 
model of PD. The lack of the transcription factor Pitx3 expressed in dopaminergic neurons in 
the midbrain results in an abnormal development of the dopaminergic system and in a selective 
loss of TH and dopamine in the striatum (Hwang et al., 2003). Therefore, aphakia mice provide 
a genetic model of the dopamine depletion in the striatum present in PD (Hwang et al., 2005; 
Ding et al., 2007).  
Immunohistochemical studies revealed that aphakia mice showed an enhanced striatal 
Gαolf expression compared to that found in the wild type naïve animals but very similar to the 
Gαolf levels observed in wild type hemiparkinsonian mice (Figure 16A). Moreover, aphakia 
mice also showed a uniform patter of Gαolf expression, in which the striosomes were indistin-
guishable from the matrix compartment. Remarkably, chronic L-DOPA treatment restored 
Gαolf protein expression in aphakia mice, reaching similar levels to those found in L-DOPA-
treated wild type animals. L-DOPA administration also re-established the normal patched pat-
tern, with a higher expression of Gαolf in the striosomes than in the matrix in both Parkinsonian 
models, 6-OHDA-lesioned and aphakia mice.  
Densitometric measurements of immunostained striata revealed a 35% of decrease in 
Gαolf protein expression in L-DOPA-treated aphakia mice compared to the saline-treated ani-
mals (Figure 16B). On the contrary, L-DOPA treatment induces a 20% of increase in striatal 
Gαolf mRNA (Figure 16C). The increase in Gαolf mRNA levels correlated well with that seen 
in the 6-OHDA-lesioned wild type mice. 
1.4. Genetic inactivation of D1R, but not D2R, increases Gαolf expression and induces 
the loss of its patchy pattern 
We next wanted to establish the role of the dopamine D1 and D2 receptor subtypes in 
Gαolf expression since Gαolf is coupled to D1 receptors. We used genetically engineered adult 
mice lacking either the dopamine D1 receptor (D1R-/-) (Moratalla et al., 1996b; Centonze et al., 
2003; Granado et al., 2008b; Espadas et al., 2012) or the dopamine D2 receptor (D2R-/-) (Kelly 
et al., 1997; Darmopil et al., 2009; Granado et al., 2011; Murer and Moratalla, 2011; Espadas et 
al., 2012).  
Analysis of serial rostrocaudal sections immunostained for Gαolf indicated that striatal 
Gαolf levels were much higher in D1R null mice than in their wild type littermates, whereas 
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Figure 16. L-DOPA decreases Gαolf expression in the striatum of aphakia mice. (A) Photomicrographs of 
serial striatal rostrocaudal sections from adult aphakia mice treated chronically with saline or L-DOPA compared 
to wild type naïve or 6-OHDA-lesioned mice treated with saline or L-DOPA, immunostained for TH and Gαolf. 
Histograms show quantifications of striatal (B) Gαolf protein measured as the proportional stained area of Gαolf-
immunoreactivity in the striatum and (C) Gαolf mRNA expressed as normalized mRNA levels to GAPDH. Data 
(mean ± SEM) were analyzed by one-way ANOVA followed by Newman-Keuls test. *p<0.01, **p<0.001 vs sa-
line. Bar = 500 µm. n=5.  
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deletion of D2R did not alter Gαolf expression (Figure 17A). In addition, genetic deletion of 
D1R induced a loss of the Gαolf expression pattern, increasing Gαolf expression in the striatal 
matrix and making striosomes indistinguishable from the surrounding matrix. On the other 
hand, the patched pattern described previously for the wild type animals was preserved in D2R-
deficient mice, which showed Gαolf-enriched striosomes. Densitometric measurements of 
negative images showed a 25% increase in Gαolf expression in D1R-/- mice compared to their 
wild type littermates (Figure 17B). Significant differences in D1R-/- mice were found by one-
way ANOVA following by Newman-Keuls test [F3,8 = 10.45; p<0.01] compared to wild type 
mice. 
Figure 17. Inactivation of D1R but not of D2R increases Gαolf expression and induces the loss of patched 
pattern. (A) Representative photomicrographs of striatal coronal sections from adult mice immunostained for 
Gαolf and their negative prints. Notice the higher expression of Gαolf and the loss of patched pattern in the stria-
tum of the D1R-/- mice. Bar = 500 mm. Histograms show (B) Gαolf protein levels measured as the proportional 
stained area of Gαolf-immunoreactivity in the striatum and (C) Gαolf mRNA levels in the striatum analyzed by RT
-qPCR and normalized to GAPDH. Data expressed as mean ± SEM were analyzed by one-way ANOVA followed 
by Newman-Keuls test. *p<0.01 vs WT D1R. n=3-5.  
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We then examined Gαolf mRNA levels by RT-qPCR to determine whether the increase in 
Gαolf protein observed in the striatum of mutant D1R-/- mice resulted from an increase in the 
transcription of the Gαolf gene and/or a post-transcriptional mechanism. The concentration of 
Gαolf transcripts was not significantly different in the striatum of either D1R-/- mice or D2R-/- 
mice compared to their littermates wild type animals (Figure 17C; [F3,15 = 0.05; p=0.98]). 
These results indicate that the increase in Gαolf protein observed in the striatum of D1R-/- mice 
is not the consequence of alterations in Gαolf mRNA levels.  
Thus, D1R seems to regulate Gαolf expression not only in a quantitative way but also its 
pattern of expression, while modifications of D2R do not affect such effects. Moreover, these 
modifications take place in a post-transcriptional level and do not result from a change in gene 
expression 
1.5. Dopamine depletion with 6-OHDA decreases Gαolf expression in D1R -/- mice 
To further elucidate the role of dopamine in Gαolf expression, we subjected D1R-/- mice 
to 6-OHDA unilateral striatal lesion. Striatal dopamine depletion decreases the elevated Gαolf 
levels found in D1R-/- mice, contrary to what we found in the wild type animals. In addition, as 
observed in the naïve D1R-/- animals, no patched pattern was detected in ipsi- and contralateral 
striatum (Figure 18A).  
Interestingly, L-DOPA treatment in D1R-/- mice was unable to modify striatal Gαolf lev-
els as happened in the wild type hemiparkinsonian animals. Immuno quantification experiments 
by image analysis showed that Gαolf levels measured in the denervated striatum of D1R-/- mice 
were 15% lower than in naïve D1R-/- mice but not different from those measured in the dyski-
netic condition, meaning that L-DOPA did not affect Gαolf expression in D1R-/- mice (Figure 
18B). Moreover, no striosome could be observed in the ipsi- and contralateral striatum of D1R 
null mice in any of the conditions. Significant differences were found by two-way ANOVA fol-
lowed by Newman-Keuls test for genotype [F1,13 = 26.83; p<0.001], treatment [F2,13 = 4.78; 
p<0.05] and genotype x treatment [F2,13 = 43.09; p<0.001]. These differences between geno-
types cannot be attributed to different striatal dopaminergic denervation, as no differences in 
TH immunostaining were detected (Figure 18C). 
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1.6. Genetic inactivation of D2R does not modify Gαolf changes in Parkinsonian and 
dyskinetic mice 
We then explored the implication of D2R in Gαolf expression changes induced by dopa-
mine using D2R deficient mice. We found that striatal dopaminergic denervation by 6-OHDA 
induced an up-regulation in Gαolf levels in D2R-/- mice similar to that found in their wild type 
littermates (Figure 19A). In addition, D2R null mice also showed the same pattern changes in 
Gαolf expression as the wild type animals, with no apparent Gαolf-enriched striosomes in the 
depleted striatum likely due to an increase in Gαolf protein in the matrix area. Quantification 
Figure 18. Dopamine depletion with 6-OHDA decreases Gαolf expression in D1R-/- mice. (A) Representative 
photomicrographs of striatal sections from WT and D1R-/- mice immunostained for Gαolf. (B) Histogram shows 
the proportional stained area of Gαolf-immunoreactivity in the striatum. (C) TH immunostaining was performed to 
confirm the efficacy of 6-OHDA lesion. Data (mean ± SEM) were analyzed by two-way ANOVA followed by 
Newman-Keuls test. *p<0.001 vs WT naïve, #p<0.001 vs D1R-/- naïve. Bar = 500 mm. n=3-4.  
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experiments revealed a 20% increase in Gαolf levels after dopamine depletion relative to the 
basal situation (Figure 19B). Significant differences were found by two-way ANOVA followed 
by Newman-Keuls test for treatment [F2,14 = 14.06; p<0.001] but not for genotype [F1,14 = 1.46; 
p=0.25]. 
Chronic L-DOPA treatment of D2R deficient mice reduced Gαolf  levels compared to 
those found in the Parkinsonian lesioned striatum. This reduction was similar to that observed 
in the wild type mice. Moreover, D2R-/- mice also showed a recovery in the patched pattern ex-
pression of Gαolf, with Gαolf-enriched striosomes, similar to that observed in wild type ani-
mals. In summary, D2R does not appear to be implicated in the regulation of Gαolf following 
dopaminergic denervation and L-DOPA treatment.  
Figure 19. Genetic deletion of D2R does not alter changes in Gαolf expression after dopamine depletion and 
L-DOPA treatment. (A) Representative photomicrographs of striatal sections from WT and D2R-/- mice immu-
nostained for Gαolf. (B) Histogram shows the proportional stained area of Gαolf-immunoreactivity in the striatum. 
(C) TH immunostaining was performed to confirm the efficacy of 6-OHDA lesion. Data (mean ± SEM) were ana-
lyzed by two-way ANOVA followed by Newman-Keuls test. *p<0.001 vs naïve condition. Bar = 500 mm. n=3-4.  
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1.7. Genetic modifications in DREAM do not alter Gαolf expression changes induced 
by 6-OHDA and L-DOPA treatment 
Once we had studied Gαolf regulation by dopamine upstream G-proteins, we then wonder 
if changes downstream could also influence Gαolf expression. We investigated the impact of 
DREAM, located downstream PKA and calcium, on striatal Gαolf levels. DREAM, a calcium-
binding protein, binds to DRE sites in the DNA and represses transcription of target genes, such 
as c-fos, Fos-related antigen-2 (fra-2) and prodynorphin, among others. This repression is re-
leased by calcium and PKA activation following dopamine stimulation of D1R. To achieve this 
goal, we used DREAM-/- mice (Cheng et al., 2002; Cebolla et al., 2008) and transgenic mice 
expressing a dominant active mutant DREAM (daDREAM) (Gomez-Villafuertes et al., 2005; 
Savignac et al., 2005).  
As expected, daDREAM and DREAM-/- mice showed the same Gαolf protein levels and 
the same patchy pattern of Gαolf-enriched striosomes as their wild type littermates (Figure 
20A). These results indicate that genetic modifications in DREAM protein do not modify basal 
Gαolf expression.  
Figure 20. DREAM does not modify Gαolf expression changes induced by dopamine depletion. (A) Repre-
sentative photomicrographs of striatal sections from adult wild type, daDREAM and DREAM-/- mice immu-
nostained for Gαolf. (B) Histogram shows the proportional stained area of Gαolf-immunoreactivity staining in the 
striatum from the three genotypes in naïve, Parkinsonian (Park) and dyskinetic (Dysk) conditions. Notice that 
modifications in DREAM protein do not alter either the levels or the pattern of Gαolf expression. Data expressed 
as mean ± SEM were analyzed by two-way ANOVA followed by Newman-Keuls test. *p<0.05 vs naïve condition. 
Bar indicates 500 µm. n=3-7.  
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Furthermore, dopamine depletion following 6-OHDA lesion induced a significant in-
crease in Gαolf expression (F2,35 = 14.74; p<0.001) of about 20% in all hemiparkinsonian mice 
compared to the levels seen in the naïve situation (Figure 20B). The uniform pattern of expres-
sion found after denervation in the wild type animals was also evident in DREAM mutant mice, 
with no distinguishable striosomes from the surrounding matrix. L-DOPA treatment restored 
Gaolf protein levels as well as the patched pattern of expression in all three genotypes. These 
results indicate that changes in DREAM protein do not affect Gαolf expression changes in-
duced by dopamine depletion or L-DOPA administration. 
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2. ROLE OF DREAM PROTEIN IN L-DOPA-INDUCED DYSKINESIA 
In the second part of my Thesis, we have studied the role of DREAM in L-DOPA-
induced dyskinesia. We target DREAM protein because is a downstream element in the cAMP-
dependent pathway and, for this reason, it could exercise a finer regulation of the target genes 
implicated in dyskinesia. To establish the role of the DREAM protein in the development of L-
DOPA-induced dyskinesia and in the associated molecular changes, we used genetically 
DREAM deficient mice (DREAM-/-) and the transgenic dominant active mutant DREAM mice 
(daDREAM).  
We have previously demonstrated that L-DOPA-induced dyskinesia is causally linked 
with hyperstimulation of D1Rs located on direct pathway medium spiny neurons of the severely 
denervated striatum (Pavón et al., 2006; Murer and Moratalla, 2011). In the dopamine-depleted 
striatum, L-DOPA activates a cAMP-dependent signaling cascade via PKA activation (Lebel et 
al., 2010; Fisone and Bezard, 2011), inducing transcriptional changes that result in increased 
expression of FosB, P-AcH3 and dynorphin-B (Darmopil et al., 2009). The magnitude of these 
molecular changes correlates with the intensity of dyskinesia.  
DREAM is a calcium-binding protein that mediates calcium- and cAMP-dependent 
transcriptional responses (Ledo et al., 2000a; Cebolla et al., 2008). As seen before, in basal 
conditions DREAM binds to DRE, located downstream from the transcription initiation site, 
repressing the transcription of target genes including prodynorphin, c-fos and Fos-related anti-
gen-2 (fra-2) (Carrión et al., 1999; Link et al., 2004). DREAM-mediated repression is reversed 
by calcium and by its PKA-dependent interaction with phospho-CREM, the cAMP responsive 
element modulator (Carrión et al., 1999; Ledo et al., 2000b, 2002; Osawa et al., 2001). 
Based on these observations and on our previous data demonstrating a close association 
between L-DOPA-induced dyskinesia and overexpression of FosB and dynorphin-B, we stud-
ied the role of DREAM in L-DOPA-induced dyskinesia. 
2.1. Wild type and mutant DREAM expression 
The first point to clarify about DREAM protein was its localization in the adult mouse 
brain. Immunohistochemical studies from brain sections revealed marked expression in stria-
tum, cortex, SN and hippocampus (Figure 21). DREAM is more abundant in the pyramidal lay-
ers from CA1 to CA3 areas in the hippocampus and in the granular layer of the dentate gyrus. 
In the striatum, DREAM is expressed in the neuropil and in the soma of large and medium 
sized striatal neurons, with a higher expression in the matrix compartment. Moreover, DREAM 
protein is abundantly expressed in the dopaminergic neurons and processes of the SNc and SNr. 
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DREAM is also found in the cerebral cortex, in all layers except the molecular one. 
In the daDREAM transgenic mice, expression of the transgene, a bi-cistronic construct 
including the daDREAM double mutant, an IRES sequence and the lacZ reporter, was driven 
by the CaMK-II alpha promoter (Figure 22A). The CaMK-II alpha promoter was chosen to 
guarantee a telencepahlic-specific expression of the transgene (Mayford et al., 1996). The lacZ 
reporter allowed us to confirm the specific expression of the daDREAM transgene by a b-
galactosidase staining. It showed high levels of transgene expression in the striatum as well as 
in the cortex and the hippocampus (Figure 22B,C). The daDREAM transgenic protein results in 
a mutant protein with the functional EF-hands and the leucine-charged reside-rich domains in-
sensitive to calcium and to CREB/CREM proteins, respectively. Thus, mutant daDREAM re-
mains bound to the DNA, inhibiting transcription. 
Figure 21. Distribution of DREAM protein in the adult mouse brain. Photomicrographs of brain sections from 
adult wild type mice immunostained for DREAM and illustrating DREAM expression in (A) the striatum, (B) the 
hippocampus and (C,C’) the substantia nigra. Scale bars indicate 500 mm (A,B,C) and 100 mm (C’).  
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2.2. Basal locomotor activity and motor coordination are normal in DREAM mutant 
mice 
From a morphological point of view, mutant mice were indistinguishable from their 
wild type littermates. No differences in weight, fertility and longevity were evident between the 
three genotypes of mice, i.e., daDREAM, DREAM-/- and wild type. In addition to these direct 
observations, we carried out behavioral tests prior to the 6-OHDA lesion to rule out any motor 
impairment in the mutant animals that could interfere with later L-DOPA behavioral studies. To 
achieve this goal, we submitted the mice to spontaneous locomotor activity and coordination 
tests. 
We used an automated multicage activity monitoring system to measure basal locomotor 
activity. Mice were first habituated to the system for two days to avoid exploratory behavior 
due to the novel environment. The third day we found that in the absence of any external chal-
lenge, daDREAM, DREAM-/- and wild type mice showed similar horizontal and vertical activ-
ity, as indicated by the number of beam breaks measured for one hour (Figure 23A,B). Ambula-
tory activity measured as total distance traveled was also similar among the three genotypes 
(Figure 23C). Over time, as the mice habituated to the environment, the number of beam breaks 
and the distance traveled diminished, with a similar profile in all three genotypes. 
To further strengthen these results, we analyzed the basal motor coordination of mutant 
mice. Animals were submitted to an accelerated version of the rotarod test, in six trials 20 min-
utes apart. No statistically significant differences between genotypes were found regarding mo-
Figure 22. Construct and expression of daDREAM transgene. (A) Schematic representation of the construct 
used for preparation of transgenic mice. (B) Coronal section of daDREAM transgenic mouse forebrain showing 
the distribution of b-galactosidase staining. (C) Sagital section of hippocampus from daDREAM transgenic mouse 
brain showing the distribution of b-galactosidase staining. Scale bars = 500 mm.  
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tor coordination (Figure 24). All animals achieved a significant increase (F2,64 = 22.38; 
p<0.001) in the latency to fall from the rotating rod at the sixth and last trial compared to the 
first trial, showing a similar capacity of motor learning in the rotarod.  
Taken together, these results indicate that modifications in DREAM protein expression 
do not modify spontaneous locomotor activity or motor coordination. 
Figure 23. Genetic modification of DREAM protein levels does not alter basal locomotor activity. (A) Hori-
zontal and (B) vertical locomotor activity (beam breaks) and (C) total distance traveled (cm) during 60 min were 
measured in a multicage activity monitoring system. Transgenic (daDREAM) and knockout (DREAM-/-) mice 
behaved similarly to wild type mice and showed similar performance in motor coordination.  
Figure 24. Modifications in DREAM do not alter basal coordination in mutant mice. Latency (s) to fall in the 
rotarod test at constant acceleration. daDREAM and DREAM-/- mice behave similarly to WT mice and show simi-
lar improvement in motor coordination following the initial performance. Data expressed as mean ± SEM were 
analyzed by two-way ANOVA with repeated measures followed by Newman-Keuls test. #p<0.01 vs. trial 1. n=10
-12.  
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2.3. DREAM modulates L-DOPA-induced dyskinesia  
To examine the role of DREAM in the development of dyskinesia, animals were unilat-
erally lesioned with 6-OHDA and treated for three weeks with 25 mg/kg of L-DOPA to gener-
ate our mouse model of dyskinesia. We assessed axial dystonia and forelimb, orofacial and lo-
comotive dyskinesia in daDREAM, DREAM-/- and the corresponding wild type littermates 40 
minutes after L-DOPA administration. L-DOPA was given daily and assessments were done 
twice a week, as described (see Material and Methods).  
 In wild type mice, all four types of dyskinetic symptoms were already apparent at the 
beginning of the treatment and progressively increased to reach a plateau in the second week of 
administration (Figure 25), similar to that found earlier (Pavón et al., 2006; Darmopil et al., 
2009). Interestingly, daDREAM mice showed a significant reduction in dyskinetic movements, 
Figure 25. DREAM overexpression in daDREAM mice decreases L-DOPA-induced dyskinesia in hemi-
parkinsonian mice. Time course of appearance of dyskinetic symptoms is shown: limb dyskinesia (Limb), orofa-
cial dyskinesia (ORF), axial dystonia (Axial) and locomotive dyskinesia (Loc). Movements were evaluated 40 
min after L-DOPA (25 mg/kg) administration at the indicated days. daDREAM mice show a lower dyskinetic 
score for limb and orofacial dyskinesia and for axial dystonia compared to wild type mice. No significant differ-
ences were found for locomotive dyskinesia. Data expressed as mean ± SEM were analyzed by two-way ANOVA 
with repeated measures followed by Newman-Keuls test. * p<0.01, ** p<0.001 vs WT. n=15.  
Results 
81 
in particular for limb (p<0.001) and orofacial (p<0.001) symptoms as well as for axial dystonia 
(p<0.001) compared to their wild type littermates. These changes were apparent from the first 
day of L-DOPA administration and lasted over the entire 3-week treatment. 
In sharp contrast, a significant enhancement in limb (p<0.05) and orofacial (p<0.01) dy-
skinesia as well as axial dystonia (p<0.05) was observed in DREAM-/- mice compared to their 
wild type littermates (Figure 26). While the wild type animals reached dyskinetic severity grade 
2-3 (indicating alternation between dyskinetic movements and short time of normal activity, 
similar to that found by Francardo et coworkers (2011) in striatal lesioned mice), DREAM-/- 
mice exhibited continuous dyskinetic behaviors, reaching the highest severity grade (3–4) on 
the rodent dyskinetic scale. Notably, no statistically significant difference in locomotive dyski-
nesia was observed among genotypes, indicating that DREAM modifications do not compro-
mise the motor stimulant effect of L-DOPA.  
Figure 26. Genetic inactivation of DREAM potentiates L-DOPA-induced dyskinesia in hemiparkinsonian 
mice. Graphs show the time course of appearance of dyskinetic symptoms evaluated 40 min after 25 mg/kg L-
DOPA administration at the indicated days: limb dyskinesia (Limb), orofacial dyskinesia (ORF), axial dystonia 
(Axial) and locomotive dyskinesia (Loc). Inactivation of DREAM in DREAM-/- mice significantly increased limb 
and orofacial dyskinesia and axial dystonia compared to wild type mice. Data expressed as mean ± SEM were 
analyzed by two-way ANOVA with repeated measures followed by Newman-Keuls test. * p<0.05, ** p<0.01, *** 
p<0.001 vs WT. n=8-12.  
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We then calculated the global dyskinetic score of daDREAM and DREAM-/- mice. Al-
though dyskinesia was observed in both daDREAM and wild type mice, the total score 
achieved by daDREAM mice was significantly lower (p<0.001) compared to wild type mice for 
all time points evaluated (Figure 27). On the other hand, the total dyskinetic score was higher in 
DREAM-/- animals compared to that reached by their wild type littermates (p<0.05), although 
this difference was smaller to that observed between the daDREAM and the wild type mice. 
Significant differences were found for genotype [F2,190 = 34.01, p<0.001], time [F5,190 = 19.34; 
p<0.001] and genotype x time [F10,190 = 2.12, p<0.05] by two-way ANOVA with repeated 
measures followed by Newman-Keuls test.  
Figure 27 DREAM content modulates the global dyskinetic score. Time course of global dyskinetic score 
(Global dysk) in daDREAM and in DREAM-/- mice compared to their wild type littermates, evaluated 40 min after 
L-DOPA (25 mg/kg) administration at the indicated days. DREAM overexpression decreased LID score for the 
entire treatment period, while inactivation of DREAM increased LID score. Global LID scores expressed as mean 
± SEM were analyzed by two-way ANOVA with repeated measures followed by Newman-Keuls test. *p<0.05, 
**p<0.001 vs WT. n=8-15.  
To look for differences in the kinetic profile of L-DOPA responses among genotypes, 
which could interfere with the development of L-DOPA-induced dyskinesia, we determined the 
duration of the dyskinetic response and the peak severity of the symptoms. To achieve this goal, 
we evaluated the time course of L-DOPA response in daDREAM and DREAM-/- mice on day 
20 of L-DOPA administration (Figure 28). Dyskinetic symptoms were scored for 1 minute 
every 20 minutes during the 160 minutes following L-DOPA administration. Dyskinesia was 
evident at 20 minute, peaked between 40 and 60 minutes, and declined significantly at 100 min-
ute after L-DOPA before disappearing at 140 minutes for both genotypes. Although the time 
course of L-DOPA response was similar in both groups of mice, daDREAM mice exhibited sig-
nificantly lower dyskinesia compared to wild type animals across the entire duration of the L-
DOPA response. Finally, there were no statistically significant differences between DREAM-/- 
Results 
83 
and wild type mice in the duration of the L-DOPA response. As in daDREAM mice, the re-
sponse was evident 20 minutes after L-DOPA and disappeared after 140 minutes. However, a 
difference was again observed in the intensity of the dyskinetic symptoms, which were stronger 
in DREAM-/- mice until 120 minutes, when the dyskinetic scores were similar for the duration 
of the effect. Significant differences were found for genotype [F2,196 = 13.51, p<0.001], time 
[F7,196 = 99.56; p<0.001] and genotype x time [F14,196 = 5.44, p<0.001] by two-way ANOVA 
with repeated measures followed by Newman-Keuls test. These temporal course results showed 
that changes in DREAM do not alter the kinetic profile of L-DOPA as demonstrated by the du-
ration of the L-DOPA response, which was similar in the three genotypes of mice.  
Figure 28. DREAM content does not alter the kinetic profile of L-DOPA. Kinetic profile of dyskinetic symp-
toms was evaluated one every 20 min during 160 min on day 20 of L-DOPA treatment. DREAM overexpression 
reduced LID score during the entire half-life of L-DOPA, while genetic inactivation of DREAM increased dyski-
nesia. Global LID scores expressed as mean ± SEM were analyzed by two-way ANOVA with repeated measures 
followed by Newman-Keuls test. *p<0.05, **p<0.01, ***p<0.001 vs WT. n=8-15.  
2.4. Antiparkinsonian effect of L-DOPA is maintained in DREAM mutant mice 
To rule out that the different dyskinetic score induced by L-DOPA in DREAM mutant 
mice was not due to an altered motor response to L-DOPA in these mice, we carried out the 
cylinder and rotarod tests to measure the antiparkinsonian effect of L-DOPA (Francardo et al., 
2011; Espadas et al., 2012). The cylinder test is used to evaluate the forelimb akinesia and 
asymmetry in unilateral rodent models of PD, by counting the contralateral and ipsilateral fore-
limb touches that the mouse performs against the surrounding glass wall. 
In the naïve situation, i.e., in the absence of any external challenge, mice used both fore-
limbs similarly (Figure 29A). However, 3 weeks after 6-OHDA lesions, when the animals are 
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completely recovered from the surgical intervention, hemiparkinsonian mice showed a signifi-
cant asymmetry in forelimb use (F2,61 = 48.228; p<0.001). Importantly, no significant differ-
ences were observed among the three genotypes, indicating that the changes in DREAM ex-
pression do not affect motor impairment induced by the lesion. Moreover, the genetic manipu-
lation of DREAM did not affect forelimb recovery after L-DOPA injection, measured 140 min-
utes post-treatment to avoid the motor interferences due to dyskinesias. Thus, daDREAM, 
DREAM-/- and wild type mice showed a significant recovery (p<0.001) of contralateral paw use 
and showed a positive response to L-DOPA, independent of the dyskinetic score. 
To further strengthen these results, we tested the mice on the rotarod to evaluate the ef-
fects of L-DOPA on motor coordination. Parkinsonian mice significantly decreased the time on 
the rotating rod with similar latency to fall in all three genotypes compared to latency before 
lesion, making evident the akinetic state of the mice (Figure 29B). Chronic L-DOPA treatment 
significantly improved motor performance and recovery of the initial latency in all three geno-
types, indicating a similar therapeutic L-DOPA response (F2,83 = 27.70; p<0.001).  
Figure 29. Genetic manipulation of DREAM does not modify the therapeutic effect of L-DOPA. (A) Fore-
limb use asymmetry was assessed with the cylinder test and (B) motor coordination with the rotarod before 
(naïve), 3 weeks after 6-OHDA lesion (parkinsonian, Park) and during chronic L-DOPA (dyskinetic, Dysk) on day 
17, 140 min post-L-DOPA (A), or on day 9, 24 hours after the administration of L-DOPA (B). Data from the cylin-
der test are expressed as % of wall contacts performed with the contralateral limb and in sec for the rotarod. Mean 
± SEM were analyzed by two-way ANOVA followed by Newman-Keuls test. #p<0.001 vs. naïve; *p<0.05, 
**p<0.01, ***p<0.001 vs. Park group. No statistically significant differences among genotypes were found in any 
of the three conditions tested, i.e., naïve, Parkinsonian and dyskinetic. n=6-9 
The performance of the mice in the rotarod after L-DOPA was measured 24 hours after 
administration to avoid exhaustion due to dyskinetic symptoms. The rotarod is a demanding test 
regarding motor condition, and the fatigue could interfere with the performance of the test. 
Moreover, recent results from our laboratory showed that L-DOPA acts for at least 4 days after 
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a chronic L-DOPA treatment (Espadas et al., 2012), thus measuring efficacy of L-DOPA 24 
hours post-administration seems reasonable and convenient. 
These results from the rotarod correlated with the previous data from the cylinder test 
and confirm that modifications in DREAM content do not alter the antiparkinsonian efficacy of 
the L-DOPA, since all animals recover motor capacities after treatment. 
As a matter of fact, the phenomenology of L-DOPA-induced dyskinesias in the rodent 
model, in terms of severity and amplitude, is conditioned by the degree of dopaminergic dener-
vation within the striatum (Winkler et al., 2002, Darmopil et al., 2009; Francardo et al., 2011). 
Thus, to exclude that the extent of the dopaminergic lesion in the three genotypes was different 
and possibly influencing the results, we assessed the percentage of striatal volume with a com-
plete loss of TH-immunoreactive fibers for each group of animals (Figure 30). We found no 
significant differences between groups (44.2 ± 2% for daDREAM, 48.7 ± 2% for DREAM-/- 
and 46.2 ± 2% for the WT mice), indicating that the volume of dopamine-depleted striatum was 
similar among all groups studied and that the different dyskinetic behavior exhibited by mutant 
mice could not be attributable to different lesion degree. 
Figure 30. Striatal lesion extent in the three studied groups. (A) Scatter diagram of the extent of striatal lesions 
assessed by percentage of striatal volume completely denervated. No statistically significant differences were 
found among genotypes by one-way ANOVA analysis. (B) Coronal sections through the lesioned striatum of mice 
from the three studied genotypes immunostained for TH. Scale bar = 500 mm.  
2.5. DREAM is expressed in direct and indirect striatal projection neurons  
The positive distributed DREAM immunostaining in the striatum indicated to us that at 
least, striatal projection neurons were able to express the protein, although it was unknown 
whether DREAM is differentially expressed in direct versus indirect pathway neurons. We ap-
proached this question by using naïve BAC-transgenic D1R-tomato mice to differentiate direct 
from indirect pathway neurons. Striatal coronal sections from BAC-transgenic D1R-tomato 
mice were immunostained for DREAM. Confocal imaging analysis showed moderate DREAM 
signal in both, D1R-positive (red fluorescence) and D1R-negative (no fluorescence) medium 
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spiny neurons (Figure 31), suggesting that DREAM is expressed in both direct and indirect 
pathway neurons. This immunolabeling was preferentially nuclear, but was also evident in the 
cytoplasm and in the neuropil.  
Figure 31. DREAM is expressed by both D1R-positive and D1R-negative medium spiny neurons. Representa-
tive high-resolution striatal confocal images of naïve BAC-transgenic D1R-tomato mice illustrating DREAM 
(green) expression in D1R-positive (red) and in D1R-negative medium spiny neurons. Hoechst (blue) stain identi-
fies the nuclei. Arrows indicate examples of dual DREAM- and D1R-positive neurons while arrowheads point to 
DREAM-positive/D1R-negative neurons. Scale bar = 25 µm.  
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We therefore investigated the effect of 6-OHDA lesion and L-DOPA treatment in 
DREAM expression. To do so, we performed RT-qPCR experiments, which demonstrated that 
L-DOPA administration to sham or lesioned animals did not modify DREAM mRNA expres-
sion in the striatum or in the substantia nigra of wild type mice (Figure 32A). TH mRNA in the 
substantia nigra was also measured in the same animals by RT-qPCR to confirm the efficacy of 
6-OHDA lesion (Figure 32B, [F2,17 = 10.54, p<0.001]). 
Figure 32. DREAM mRNA levels are not modified by dopamine depletion or L-DOPA treatment. Histo-
grams show DREAM (A) and TH (B) mRNAs levels analyzed by RT-qPCR and normalized to 18S mRNA in wild 
type mice. (B) The TH mRNA levels in substantia nigra (SN) were quantified to confirm the efficacy of 6-OHDA 
lesion. Data (mean ± SEM) are expressed as normalized values and analyzed by one-way ANOVA followed by 
Newman-Keuls test. *p<0.01 vs. WT naïve animals. n=5-7.  
2.6. DREAM regulates key molecular determinants of LID 
Several studies have correlated the increased levels of FosB, dynorhin-B and P-AcH3 in 
the dorsolateral lesioned striatum with the appearance of L-DOPA-induced dyskinesia 
(Andersson et al., 1999; Pavón et al., 2006; Darmopil et al., 2009). We evaluated the effect of 
the genetic modification of DREAM on the striatal levels of these markers after chronic L-
DOPA administration in hemiparkinsonian mice. To carry out the molecular studies, animals 
were sacrificed 1 hour after the last L-DOPA injection, in the peak moment, on day 20 of 
chronic treatment, when molecular changes due to L-DOPA are fully established. Coronal stri-
atal sections were immunostained for FosB, dynorhin-B and P-AcH3. The number of stained 
nuclei (for FosB and P-AcH3) as well as the proportional stained area (for dynorphin-B) were 
measured in 5 serial rostrocaudal sections per animal and 3 counting frames with the aid of an 
image analysis system. 
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As expected, L-DOPA treatment induced marked expression of FosB in the dorsolateral 
part of the lesioned striatum, sparing the unlesioned side in wild type animals. Notably, the 
number of FosB-positive neurons was threefold lower in the lesioned striatum of daDREAM 
transgenic mice and just slightly increased in DREAM-/- mice compared to wild type mice 
(Figure 33, [F2,47 = 31.14; p<0.001]).  These results are in agreement with the dyskinetic scores 
found for daDREAM and DREAM-/- mice.  
Figure 33. DREAM overexpression reduces, while its inactivation potentiates FosB protein expression in-
duced by L-DOPA. (A) High power photomicrographs of unlesioned and lesioned striatum of WT, daDREAM 
and DREAM-/- mice sacrificed 1 hour after the last L-DOPA injection, immunostained for FosB. Scale bar = 50 
µm. (B) Histograms represent the quantification of FosB-immunoreactive positive nuclei in the unlesioned and 
lesioned striatum of hemiparkinsonian WT, daDREAM and DREAM-/- mice. Note the higher expression in 
DREAM-/- compared to WT and the decreased expression in daDREAM mice. Data (mean ± SEM) representing 
positive nuclei were analyzed by two-way ANOVA followed by Newman-Keuls test. *p<0.01, **p<0.001 vs le-
sioned WT.  
Furthermore, scanning of the dynorphin-B-positive area, including cytoplasm and neu-
ropil, revealed a 39% reduction and a 65% increase relative to the total area scanned in 
daDREAM and DREAM-/- mice, respectively (Figure 34, [F2,24 = 12.13; p<0.001]). 
Finally, phosphorylation on Ser10-acetyl-Lys14 histone 3 was significantly modified in 
the striatum ipsilateral to the lesion with a 2.5-fold decrease in the number of P-AcH3-positive 
nuclei in daDREAM mice and a 1.5-fold increase in DREAM-/- mice compared to wild type 
mice (Figure 35, [F2,41 = 21.67; p<0.001]). 
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Figure 34. DREAM overexpression reduces, while its inactivation potentiates dynorphin-B protein expres-
sion induced by L-DOPA. (A) Representative photomicrographs of unlesioned and lesioned striatum of WT, 
daDREAM and DREAM-/- mice sacrificed 1 hour after the last L-DOPA injection, immunostained for dynorphin-B 
(DynB). Scale bar = 50 µm. (B) Histograms represent the quantification of the proportional dynorphin-B immuno-
reactive area in the unlesioned and lesioned striatum of hemiparkinsonian WT, daDREAM and DREAM-/- mice. 
Data (mean ± SEM) representing proportional stained area were analyzed by two-way ANOVA followed by New-
man-Keuls test. *p<0.01, **p<0.001 vs lesioned WT.  
Figure 35. DREAM regulates P-AcH3 expression induced by L-DOPA. (A) High power photomicrographs of 
unlesioned and lesioned striatum of L-DOPA-treated WT, daDREAM and DREAM-/- mice, immunostained for P-
AcH3. Scale bar = 50 µm. (B) Histograms represent the quantification of P-AcH3 -immunoreactive positive nuclei 
in the unlesioned and lesioned. DREAM overexpression reduces, while its inactivation potentiates P-AcH3 expres-
sion induced by L-DOPA. Data (mean ± SEM) representing positive nuclei were analyzed by two-way ANOVA 
followed by Newman-Keuls test. *p<0.01, **p<0.001 vs lesioned WT.  
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The unlesioned striatum served as the negative control for these experiments: no statisti-
cally significant differences were found in any of these molecular markers in the unlesioned 
striatum of daDREAM, DREAM-/- and wild type mice. Furthermore, as an additional control 
for the specificity of these changes, we verified that the expression of L-DOPA-induced mo-
lecular determinants was strictly restricted to the completely denervated striatal area (Figure 
36), as we have shown before (Darmopil et al., 2009; Murer and Moratalla, 2011; Suárez et al., 
2014). These results indicate that genetic manipulation of DREAM does not modify the expres-
sion pattern of the molecular markers of dyskinesia in mice. These findings correlate well with 
Figure 36. Genetic manipulation of DREAM does not alter the expression pattern of key molecular determi-
nants induced by chronic L-DOPA in the lesioned striatum. Photomicrographs of adjacent striatal sections 
from WT, daDREAM and DREAM-/- mice sacrificed 1 hour after the last L-DOPA injection and immunostained 
for TH, FosB, P-AcH3 and dynorphin-B (DynB). Chronic L-DOPA administration induces marked FosB, P-AcH3 
and dynorphin-B expression in the completely denervated striatal areas. Note that genetic manipulation of 
DREAM does not modify the expression pattern of molecular markers of dyskinesia. Scale bar = 500 µm.  
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our behavioral results and implicate DREAM in the regulation of FosB, dynorphin-B and P -
AcH3 levels. 
In line with the results from the immunohistochemistry experiments showed before, 
mRNA levels were analyzed to determine whether the observed changes in FosB and dynorphin
-B expression were a consequence of modifications in a translational level or were due to 
changes in the expression of the genes under investigation. To answer this question, we carried 
out RT-qPCR experiments with control, unlesioned and lesioned striata. As expected from our 
previous results, L-DOPA dramatically increased FosB mRNA in the denervated striatum of 
wild type, daDREAM and DREAM-/- animals. Remarkably, in daDREAM mice this increase 
was significantly reduced compared to wild type mice (Figure 37A). Significant differences 
were found for genotype [F2,40 = 3.29, p<0.05], treatment [F2,40 = 96.74; p<0.001] and genotype 
x time [F4,40 = 4.52, p<0.01] by two-way ANOVA with repeated measures followed by New-
man-Keuls test. Correlating with these findings, although L-DOPA treatment increased dynor-
phin-B mRNA levels in the striatum of DREAM-/- and wild type lesioned mice, this increase 
was not evident in the daDREAM mice (Figure 37B). No differences were found in sham and 
in unlesioned striatum between genotypes. 
Figure 37. DREAM regulates L-DOPA induced FosB and DynB mRNAs expression in the denervated stria-
tum. Histograms show FosB (A) and dynorphin-B (DynB) (B) mRNAs analyzed by RT-qPCR and normalized to 
GAPDH mRNA as reference gene. Note that L-DOPA induces both FosB and dynorphin-B transcripts up-
regulation in the lesioned striatum of DREAM-/- and WT mice. Whereas, overexpression of DREAM diminishes 
FosB and blocks DynB mRNA up-regulation induced by L-DOPA. Data are expressed as normalized values (mean 
± SEM) and analyzed by two-way ANOVA followed by Newman-Keuls test. *p<0.01, **p<0.001 vs. WT sham-
operated animals; #p<0.001 vs. WT lesioned + L-DOPA. n=4-7.  
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2.7. LID-associated phosphorylation of GluR1 is attenuated in daDREAM mice 
It has been well documented in the literature that chronic L-DOPA administration pro-
duces a PKA-dependent hyperphosphorylation at serine 845 of the GluR1 subunit of the gluta-
mate AMPA receptor in the striatum of 6-OHDA lesioned mice (Santini et al., 2007) and 
MPTP-lesioned monkeys (Santini et al., 2010). Therefore, we examined whether the genetic 
modification of DREAM protein modifies the phosphorylation state of GluR1 induced by L-
DOPA. Analysis of striatal extracts by western blot showed that L-DOPA treatment provokes 
an increase in P-GluR1 levels in wild type lesioned mice, as expected. This increase was evi-
dent also in the DREAM-/- mice; however, DREAM overexpression in daDREAM mice inhib-
ited the hyperphosphorylation of GluR1 induced by L-DOPA (Figure 38A). Significant differ-
ences for genotype [F2,55 = 3.23, p<0.05] and for treatment [F2,55 = 12.77, p<0.001] were found 
by two-way ANOVA followed by Newman-Keuls test. In parallel, measurement of levels of 
TH protein confirmed a similar efficacy of the 6-OHDA lesion in all samples (Figure 38B).  
Figure 38. DREAM overexpression inhibits L-DOPA-induced phosphorylation of GluR1 at Ser845. Upper 
panels show representative autoradiograms of P-GluR1 (A) and TH (B) western blots of extracts from sham-
operated, unlesioned (U) and lesioned (L) striatum of WT, daDREAM and DREAM-/- mice chronically treated 
with 25 mg/kg L-DOPA. Lower panels show the quantification of western blots in triplicates. (A) Chronic L-
DOPA increases GluR1-phosphorylation at Ser845 in DREAM-/- and WT mice, whereas DREAM overexpression 
blocks it. (B) TH levels were quantified to confirm the efficacy of 6-OHDA lesion and no statistically significant 
differences were found among genotypes. Relative intensities versus loading control actin (normalized to WT 
Sham) were analyzed by two-way ANOVA followed by Newman-Keuls test. #p<0.05 vs WT lesioned + L-DOPA, 
*p<0.01, **p<0.001 vs WT sham-operated mice. n=4-5.  
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  The results presented in this Thesis pertain to Parkinson’s disease (PD) which is one of 
the most common neurodegenerative disorders. The central neuropathology of PD is the degen-
eration of dopaminergic neurons in the substantia nigra, leading to dramatic striatal dopamine 
depletion, but the etiology and mechanisms of this disease are not fully understood. Despite ex-
tensive investigation aimed at finding new therapeutic approaches, the dopamine precursor 
molecule L-DOPA remains the most effective and widely used non-invasive therapy for PD. 
However, chronic treatment and disease progression cause the appearance of abnormal involun-
tary movements known as dyskinesia in the vast majority of patients. L-DOPA-induced dyski-
nesia interferes significantly with normal motor activity and persists unless L-DOPA dosages 
are reduced below therapeutic levels. Thus, controlling dyskinetic symptoms is one of the major 
challenges in PD therapy. Despite the progress made in recent years, the intracellular signaling 
mechanisms implicated in L-DOPA-induced dyskinesia are not fully established. 
The results presented here shed some light on these mechanisms by specifically investi-
gated the roles of two important proteins. In the first part of this discussion, I will be presenting 
the results and the interpretation regarding Gαolf protein (the olfactory type G-protein α subunit 
which couples D1R to adenylyl cyclase). In the second part, I will be presenting the results 
about DREAM (downstream regulatory element antagonist modulator) protein and its possible 
therapeutic implications in L-DOPA-induced dyskinesia. 
1. ROLE OF DOPAMINE AND DOPAMINE RECEPTORS IN GαOLF EXPRESSION 
The findings we described in this thesis demonstrate that striatal Gαolf expression is 
regulated by dopamine and by dopamine D1 receptor. The striosomal-matrix pattern that char-
acterizes striatal Gαolf expression is loss in the dopamine depleted striatum and slightly nor-
malized after chronic L-DOPA treatment in mice. These changes in the expression pattern are 
accompanied by modifications in Gαolf levels, showing an increase in the protein concentra-
tions following striatal denervation and a reestablishment after L-DOPA administration. Impor-
tantly, this regulation is not evident in D1R null mice, which show not only a higher expression 
of Gαolf but also a complete loss of the striosomal-matrix pattern in the naïve situation. More-
over, dopaminergic denervation induces a decrease of Gαolf in the 6-OHDA-lesioned striatum 
of hemiparkinsonian D1R-/- mice and L-DOPA treatment does not restore either levels or pat-
tern of Gαolf expression in these animals. On the contrary, dopamine D2 receptors are not in-
volved in these changes as D2R null mice show the same expression pattern as their wild type 
littermates. In the same line, modifications in the calcium binding protein DREAM, located 
downstream from D1R/PKA pathway, do not alter the expression profile of the Gαolf protein.  
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1.1  Gαolf is expressed in the striatum with a striosomal-matrix pattern 
In this work, we first examined the localization pattern of Gαolf in the striosomal-matrix 
system of naïve adult mice. Gαolf protein was preferentially expressed in the striosomal com-
partment of the striatum, as previously shown by Sako and coworkers (2010). Gαolf protein 
couples D1R to adenylyl cylclase (Zhuang et al., 2000; Corvol et al., 2001) but, surprisingly, 
Gαolf and D1R are not equally distributed in the striatum. While Gαolf is more concentrated in 
the striosomes, D1R is homogeneously expressed in all the striatum, without apparent compart-
mentalization from P10 onwards (Kim et al., 2002). This divergence in the expression pattern 
could be due to the presence of “spare” D1R not coupled to adenylyl cyclase in the striatum 
(Hess et al., 1987; Hervé et al., 1989). According to Hess and coworkers (1987), this popula-
tion corresponds approximately to 40 % of the total population of D1R. The higher density of 
these “spare” D1Rs in the matrix than in the striosomal compartments could be related to their 
different developmental origin, which indicates that striosomes may form an ontogenetic unit 
(Graybiel and Hickey, 1982) with different characteristics than matrix elements.  
1.2  Dopamine depletion increases striatal Gαolf expression level 
Following dopamine depletion by 6-OHDA administration, wild type animals showed a 
significant increase in Gαolf protein expression in the striatum, in line with previous works 
(Hervé et al., 1993; Marcotte et al., 1994; Penit-Soria et al., 1997; Corvol et al., 2004; Rangel-
Barajas et al., 2011; Alcacer et al., 2012). The ability of dopamine to stimulate adenylyl cyclase 
and PKA via activation of D1R is enhanced in PD patients and in experimental animals after 
dopamine depletion (Tong et al., 2004; Santini et al., 2008). This hyper-responsiveness of D1R 
in the denervated striatum could be attributed to the increased levels of Gαolf. Furthermore, 
studies using electron microscopy also support this hypothesis. Thus, Gαolf up-regulation takes 
place in the plasma membrane of projection neurons, where it is functionally associated with 
D1R (Corvol et al., 2004).  
In line with the increase of Gαolf found in 6-OHDA-lesioned mice, previous works have 
reported changes in Gαolf expression following variations in dopamine levels. Treatment with a 
neurotoxic methamphetamine regimen decreases the dopaminergic tone and increases Gαolf 
expression in the striatum of wild type mice (Boikess et al., 2010). On the other hand, deletion 
of the dopamine transporter in DAT knockout mice induces an increase in the extracellular con-
centration of dopamine along with a decrease in Gαolf protein expression (Hervé et al., 2001). 
Taken together all these results, we suggest that dopamine regulates Gαolf expression and that a 
negative correlation exists between the striatal dopaminergic tone and the striatal Gαolf levels.  
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In the striatum, Gαolf protein not only couples adenylyl cyclase to D1R, but also to 
adenosine A2a receptors (A2aR) in D2R-bearing projection neurons (Corvol et al., 2001). The 
increase in Gαolf levels could also be due to a reduction in the stimulation of A2aR since Gαolf 
expression is regulated by receptor usage (Corvol et al., 2001). Previous findings from Dr. 
Morrelli’s group support this idea since extracellular adenosine levels, measured by in vivo mi-
crodialysis, were significantly lower (-35%) in the dopamine depleted striatum fifteen days af-
ter 6-OHDA infusion (Pinna et al., 2002). The decrease in adenosine transmission and the sub-
sequent diminution of A2aR stimulation following nigrostriatal dopamine neuron degeneration 
should induce the accumulation of Gαolf protein. The increase in Gαolf would render A2aR 
hypersensible to adenosine stimulation therefore inducing the hyperactivity of the indirect path-
way characteristic of PD. Correlating with this, an increase in adenylyl cyclase in response to 
A2a agonist has been seen in dopamine depleted striatum suggesting a hypersensitivity of A2aR 
(Premont et al., 1979). 
1.3  Dopamine depletion induces the loss of striatal Gαolf expression pattern  
In addition, we provide evidence for the first time that the increase in Gαolf protein fol-
lowing dopamine depletion is accompanied by a loss in the compartmentalization pattern of ex-
pression, suggesting that the increase in Gαolf protein takes place mainly in the matrix compart-
ment. It is not known whether there is differential vulnerability of dopamine in striosome and 
matrix compartments in PD. However, in a primate model of Parkinsonism generated by expo-
sure to low-dose of MPTP, the dopamine-containing input to striosomes was found to be rela-
tively spared in the caudal striatum, whereas dopaminergic inputs to the matrix were severely 
diminished (Moratalla et al., 1992). The predominant loss of dopaminergic activity in the ma-
trix compartment at caudal (sensorimotor) striatum might result in paucity of movement, 
thereby resulting in hypokinetic Parkinsonian symptoms. Moreover, the decrease of the dopa-
minergic tone in the matrix compartment in the Parkinsonian situation could be the cause of 
increased Gαolf expression in this area, as dopamine can regulate Gαolf expression. 
1.4  L-DOPA restores striatal Gαolf expression levels 
In agreement with the regulatory role of dopamine on Gαolf levels, 3-week treatment 
with L-DOPA reversed Gαolf up-regulation in the striatum of hemiparkinsonian mice. These 
results are consistent with previous data from dyskinetic rats (Corvol et al., 2004; Rangel-
Barajas et al., 2011). However, it should be noted that persistent increase in Gαolf levels was 
recently reported in dyskinetic L-DOPA-treated mice (Alcacer et al., 2012), in contrast to our 
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results. This discrepancy could result from the different measurement methodology. While Dr. 
Alcacer’s group compares Gαolf protein levels between the lesioned and the non-lesioned stria-
tum, we always compare protein measures to the naïve situation. Previous works have reported 
an increase in TH levels (Schlachetzki et al., 2014) as well as in dopamine (Espadas et al., 
2012; Del-Bel et al., 2013) in the non-lesioned hemisphere of the 6-OHDA model of PD. These 
data, along with the fact that L-DOPA is administered systemically, allow us to suggest that 
Gαolf expression could be also modified in the non-lesioned striatum compared to a naïve 
situation. Thus, comparisons between lesioned and naïve striatum seems to be a more accurate 
measure of L-DOPA impact on striatal Gαolf protein expression. 
The reduction in the Gαolf protein levels following chronic L-DOPA treatment could be 
due to the reported increase in the G protein coupling efficiency at the levels of D1R in dyski-
netic monkeys (Aubert et al., 2005). So, the hyper-responsiveness of the D1R/PKA pathway 
induced by L-DOPA may not be mediated solely by an increase in D1R levels (Gerfen et al., 
1990; Hervé et al., 1992; Hurley et al., 2001) or an increase in the Golf protein expression, but 
their coupling.  
In addition to this mechanism, and in line with the idea that receptor usage can control 
Gαolf expression, an abnormal increase in A2a signaling has been reported in the striatum of 6-
OHDA-lesioned rats, MPTP-treated primates as well as in PD patients chronically treated with 
L-DOPA (Pinna et al., 2002; Calon et al., 2004; Tomiyama et al., 2004). The prevailing tone of 
the A2aR following long-term L-DOPA administration could contribute to the aberrant de-
crease in Gαolf protein levels that is found in the dopamine depleted striatum. 
1.5  L-DOPA restores striatal Gαolf expression pattern 
Interestingly, our data show that L-DOPA treatment not only restores Gαolf protein con-
centration in the denervated striatum but also its striosomal-matrix characteristic expression 
pattern, diminishing Gαolf levels in the matrix compartment. These findings correlate with the 
expression pattern of two regulators of ERK signaling pathway (Crittenden et al., 2009), which 
is directly involved in L-DOPA-induced dyskinesia (Pavón et al., 2006; Darmopil et al., 2009). 
Crittenden and coworkers reported that CalDAG-GEFII gene, an ERK activator, is strongly up-
regulated in a rat model of L-DOPA-induced dyskinesia, and has a striking striosome-enriched 
pattern. By contrast, the matrix-enriched gene CalDAG-GEFI is down-regulated in this model. 
Taken together, these data suggest that striosomal neurons are over-activated relative to the ma-
trix neurons in L-DOPA-induced dyskinesia. Interestingly, an imbalance in the activity of the 
two compartments favouring striosomes over matrix has been suggested to take place in dopa-
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mine-dependent stereotypies (Moratalla et al., 1996c; Canales and Graybiel, 2000; Saka et al., 
2004). Viewed in this context, our findings raise the possibility that the preferential striosomal 
expression of Gαolf could also participate in the development of L-DOPA-induced dyskinesia. 
1.6  Regulation of Gαolf by dopamine takes place in a post-transcriptional level 
Intriguingly, changes in Gαolf protein are not linked to parallel modifications in Gαolf 
mRNA. Despite the increase of Gαolf protein in hemiparkinsonian mice, our RT-qPCR experi-
ments showed that the concentration of Gαolf transcripts did not vary significantly in the 6-
OHDA-lesioned striatum, in agreement with previous findings by Northern blot (Hervé et al., 
1993). Dr. Hervé raises the possibility that lack of stimulation in dopamine depleted striatum 
could lower the Gαolf degradation rate and lead to accumulation of the protein (Hervé et al., 
2001), without a concomitant increase in the Gαolf mRNA. In line with this idea, L-DOPA in-
duces opposite changes in Gαolf protein and mRNA. We described by the first time that while 
L-DOPA reduces Gαolf protein, transcripts are increased in dyskinetic mice. This finding is 
supported by several studies on Gαs (the stimulatory Gα ubiquitous isoform) that is a protein 
very close to Gαolf. In cell culture, long-lasting stimulation of Gαs induced a down-regulation 
of this protein (Adie and Milligan, 1994) by releasing Gαs from membranes along with an en-
hanced degradation rate (Levis and Bourne, 1992; Yajima et al., 1998). We propose that in the 
dyskinetic scenario, L-DOPA stimulation of Gαolf also induces a down-regulation of the Gαolf 
protein probably due to an enhanced degradation and a concomitant enhanced transcription 
process. However, further studies are needed to confirm this hypothesis. 
1.7  Modifications in striatal Gαolf expression are not due to chemical lesions but to 
dopamine stimulation 
Pitx3 is a homeodomain transcription factor expressed in dopaminergic neurons in the 
brain and is essential for the normal development of the midbrain dopaminergic system (Jacobs 
et al., 2007, 2009). Inactivation of Pitx3 in aphakia mice induces selective loss of dopaminergic 
neurons in the SNc and, as a consequence, major dopamine depletion in the striatum, providing 
a genetic model of PD (Hwang et al., 2003; Ding et al., 2007, 2011). Importantly, the results 
obtained in 6-OHDA lesioned wild type mice were corroborated in aphakia mice. Thus, in this 
genetic model of PD we found an increase in striatal Gαolf levels compared to those found in 
the wild type mice and very similar to those measured in 6-OHDA-lesioned mice. In the same 
line, L-DOPA treatment also restored Gαolf protein expression in aphakia mice. These data al-
low us to suggest that the results obtained are not due to the lesion procedure but to the dopa-
mine deficit found in both 6-OHDA lesioned and aphakia mice.  
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1.8  Dopamine D1 receptor regulates Gαolf expression in the striatum 
Importantly, genetic inactivation of D1R results not only in an increase of Gαolf expres-
sion, as seen by Dr. Hervé’s group (2001) by Western blot, but also in a loss of the compart-
mentalized distribution of Gαolf protein as shown by our immunohistochemical results. This 
loss of pattern is in line with previous results obtained by Xu and colleagues (1994), who 
showed a loss in the characteristic striosomal dynorphin immunostaining in D1R null mice. The 
loss of Gαolf pattern in D1R deficient mice could be due to the differentially strong develop-
mental expression of the D1R in the striosomes. Besides, we suggest that there might be devel-
opmental effects to compensate for the loss of D1R in these mice.  
On the other hand, our RT-qPCR results showed no difference in Gαolf mRNA between 
D1R null mice and wild type, indicating that changes in Gαolf occur at a post-transcriptional 
level and do not result from a change in gene expression. This hypothesis is supported by the 
homogenous patter of Gαolf mRNA expression throughout striatal development in rats 
(Sakagami et al., 1995), which contrasts with the striosomal-matrix patched pattern described in 
this work. Taken together, our results suggest that D1R regulates both protein level and expres-
sion pattern of Gαolf in basal conditions. 
Contrary to that found in wild type animals, deletion of D1R in D1R knockout mice de-
creases Gαolf expression in the dopamine depleted striatum. These results are in agreement 
with previous findings in cocaine-treated mice (Zhang et al., 2002), where cocaine binds to the 
dopamine transporter to block dopamine reuptake. Thus, dopamine stimulation is constant in 
this situation. Zhang’s group (2002) reported an increase in the Gαolf protein levels in this sce-
nario. The opposite happens in the denervated striatum of D1R-/- mice, where there is no dopa-
mine stimulation. D1R null mice showed a decrease in Gαolf protein expression after 6-OHDA 
lesion. Significantly, chronic L-DOPA treatment did not modify Gαolf expression in D1R 
knockout mice. The lack of effect of L-DOPA on Gαolf expression in these mice correlated 
with previous findings from our laboratory, where it was shown that D1R is causally and neces-
sary linked with L-DOPA-induced dyskinesia (Darmopil et al., 2009). In that work it was dem-
onstrated that D1R is required not only for the development of the L-DOPA-induced dyskinetic 
symptoms but also for the induction of the associated molecular changes, including FosB and 
dynorphin-B expression.  Thus, stimulation by L-DOPA does not produce changes in elements 
downstream from D1R in D1R knockout mice, supporting our results with Gαolf protein ex-
pression. 
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1.9  Dopamine D2 receptor is not implicated in the regulation of striatal Gαolf  
In relation to D2R, our data demonstrate that D2R is not implicated in the regulation of 
Gαolf expression. Genetic deletion of D2R in D2R null mice does not alter either levels or pat-
tern expression of Gαolf in any of the studied situations, i.e., naïve, Parkinsonian and dyski-
netic. This is in agreement with previous studies suggesting that striatonigral activity is not in-
creased in D2R deficient mice (Baik et al., 1995; Kelly et al., 1998) and that Gαolf mRNA lev-
els are not modified in these animals (Zahniser et al., 2000). Interestingly, this latter work from 
Dr. Fredholm’s group reported a reduction in A2a function in mice lacking D2R. Regarding 
their in situ hybridization experiments, which show same concentrations of Gαolf transcripts in 
both D2R-/- and wild type mice, they suggest that the decreased A2a activity could be due to a 
functional uncoupling of A2aR and Gαolf, and not to a lower expression of Gαolf. Our results 
corroborate this hypothesis since we found similar amounts of protein and equal expression pat-
tern of Gαolf in both genotypes of mice.  
1.10  Genetic modifications of DREAM protein, located downstream from D1R acti-
vation, do not affect Gαolf expression. 
Finally, our results suggest that Gαolf levels are not regulated by D1R-dependent signal-
ing downstream from cAMP stimulation. We found that genetic modification of DREAM pro-
tein, located downstream from the cAMP-regulated elements, do not induce any changes in the 
level or in the expression patter of Gαolf. This correlates with previous findings in mice lacking 
DARPP-32, which is also located downstream from the cAMP-regulated protein phosphoryla-
tion pathway (Hervé et al., 2001, unpublished observations). 
In summary, this study allows a better understanding of the mechanisms implicated in 
the regulation of striatal Gαolf expression. Our results strongly suggest a homeostatic regulation 
of Gαolf expression by dopamine, with a negative correlation between their concentrations. 
Moreover, our data clearly show that whereas D2R does not influence Gαolf expression, D1R is 
necessary for an accurate regulation of both levels and pattern expression of Gαolf. These re-
sults shed light on the mechanisms underlying the pathophysiology of PD and L-DOPA-
induced dyskinesia and indicate that the striosomal-matrix system plays an important role in 
both pathologies. 
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2. ROLE OF DREAM PROTEIN IN L-DOPA-INDUCED DYSKINESIA AND IN THE 
ASSOCATED MOLECULAR CHANGES 
In this study we have provided evidence that the DREAM protein plays a modulatory 
role in the establishment and development of L-DOPA-induced dyskinesia in mice and in the 
underlying molecular changes within the denervated striatum. Overexpression of a dominant 
active version of DREAM in transgenic mice dramatically reduced L-DOPA-induced dy-
skinesia, whereas genetic inactivation of DREAM increased dyskinetic symptoms (i.e. oro-
facial and limb dyskinesia and axial dystonia). In strict correspondence with the behavioral ob-
servations, molecular markers of dyskinesia induced by chronic L-DOPA treatment, including 
FosB, dynorphin-B, P-AcH3 and P-GluR1, were decreased in daDREAM mice but increased in 
DREAM knockout mice. Importantly, modifications in DREAM protein did not alter the kinetic 
profile or the antiparkinsonian efficacy of L-DOPA, suggesting that modulation of DREAM 
function could serve as an intervention target in therapies designed to alleviate L-DOPA-
induced dyskinesia without interfering with the beneficial effects of L-DOPA treatment. 
2.1  DREAM regulates L-DOPA-induced dyskinesia without alter either basal loco-
motor activity or antiparkinsonian efficacy of L-DOPA 
In our behavioral analysis, we first tested spontaneous locomotor activity and motor co-
ordination to rule out any motor impairment in mutant mice, which could interfere with the dy-
skinetic experiments. Performance in the open field and in the rotarod showed that mutant mice 
were indistinguishable from their wild type littermates, in agreement with previous observations 
in naïve DREAM-/- (Cheng et al., 2002; Alexander et al., 2009) and daDREAM (Dierssen et al., 
2012) adult mutant mice. These results suggest that the differences observed in L-DOPA-
induced dyskinesia among genotypes are not due to any motor impairment, but rather to the 
modifications related to DREAM levels. 
The main finding of this study is that, in our mouse model of L-DOPA-induced dyskine-
sia, dyskinetic symptoms generated by repeated administration of L-DOPA are increased in 
DREAM-deficient mice, whereas overactivation of DREAM in daDREAM animals diminishes 
dyskinesias. Importantly, dyskinetic differences among genotypes after L-DOPA treatment are 
not due to alterations of the kinetic profile of L-DOPA by DREAM, as all animals showed a 
similar duration of the L-DOPA response. Interestingly, mutant mice displayed similar motor 
performance skills in the cylinder and rotarod tests after L-DOPA administration, demonstrat-
ing that the antiparkinsonian effect of L-DOPA is preserved in mutant animals despite DREAM 
modifications.  
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2.2  DREAM represses FosB and dynorphin-B expression in direct pathway neurons 
DREAM is a multi-functional calcium binding protein (Naranjo and Mellström, 2012) 
that acts as a transcriptional repressor to regulate activity-dependent gene expression through 
direct interaction with regulatory sites in the DNA (Carrión et al., 1999). Our inmunnohisto-
chemical studies revealed high levels of DREAM protein in the striatum, the cortex, the hippo-
campus and the substantia nigra of mouse brain, in line with previous immunohistochemical 
and in situ hybridization works (Spreafico et al., 2001; Xiong et al., 2004; Duncan et al., 2009). 
In particular, immunohistochemical studies performed by the Weickert’s group (2009) indicate 
that DREAM is expressed in the neuropil and in the soma of large and medium sized striatal 
neurons. Our data show now that DREAM is also present in the nucleus of striatal projection 
neurons, including D1R-positive neurons. In these neurons, increased expression of FosB and 
dynorphin-B after L-DOPA treatment correlates with dyskinesia in: PD patients (Piccini et al., 
1997; Tekumalla et al., 2001), MPTP-treated monkeys (Berton et al., 2009; Tamim et al., 
2010), and in 6-OHDA-treated rats (Andersson et al., 1999) and mice (Pavón et al., 2006; Dar-
mopil et al., 2009; Suárez et al., 2014). Thus, transcriptional repression of FosB and prodynor-
phin genes in daDREAM mice could be directly related to the observed reduction in L-DOPA-
induced dyskinesia development.  
Correlating with the behavioral response to L-DOPA, our immunohistochemistry results 
show that overexpression of daDREAM diminishes FosB and dynorphin-B protein expression 
induced by L-DOPA in denervated striatal neurons, while genetic inactivation of DREAM in-
duces the opposite effect. The small increase of FosB and dynorphin-B protein expression ob-
served in the striatum of DREAM-deficient mice after L-DOPA is in agreement with similar 
increases observed previously in the spinal cord of DREAM-/- mice (Cheng et al., 2002).  
However, the RT-qPCR experiments showed that this modulation exerted by DREAM 
is more evident in daDREAM mice, in which we found a 50% decrease in FosB mRNA and a 
blockade of dynorphin mRNA increase after L-DOPA treatment. In the DREAM-/- mice we did 
not see any increase, either in FosB or in dynorphin mRNA levels compared to wild type mice 
as would have been expected, despite the small but significant increase observed in both pro-
teins after L-DOPA treatment compared to wild type mice. This discrepancy between mRNA 
and protein levels could be due to the methodology. While the immnuhistochemistry allows us 
to selectively analyze the complete denervated striatal areas, where the molecular changes takes 
place (Pavón et al., 2006; Darmopil et al., 2009; Suárez et al., 2014), in the RT-qPCR experi-
ments the entire dorsal striatum is analyzed. Thus, small changes in FosB or/and dynorphin ex-
pression may go unnoticed. 
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DREAM represses the transcription of the immediate early genes Fos-related antigen-2 
(fra-2) and c-fos as well as prodynorphin by binding to DRE sites located in the 5’-untranslated 
sequence downstream from the TATA box (Carrión et al., 1999; Link et al., 2004). Although 
not previously studied, taken together our data indicate that DREAM may also repress FosB 
transcription, consistent with the presence of two DRE sites in this gene (Lazo et al., 1992).  
In addition to DREAM regulation, dynorphin-B expression is also regulated by D1R 
activation (Moratalla et al., 1996b) and by binding of Fos/Jun heterodimers to an AP-1 site in 
the prodynorphin gene (Naranjo et al., 1991). Moreover, overexpression of FosB after L-DOPA 
treatment induces a concomitant increase of dynorphin-B expression in the 6-OHDA lesioned 
striatum (Andersson et al., 1999). Therefore, our data support the notion that DREAM exerts a 
double synergistic effect: directly, blocking prodynorphin transcription by anchoring to its DRE 
site, and indirectly, diminishing FosB expression, resulting in dynorphin-B down-regulation via 
AP-1. This double synergistic effect of DREAM could explain our RT-qPCR results, which 
show that overexpression of DREAM in daDREAM mice completely inhibits L-DOPA-induced 
up-regulation of dynorphin mRNA, whereas this inhibition is only partial for FosB. 
2.3  DREAM decreases L-DOPA-induced dyskinesia also by non-transcriptional 
mechanisms: role of NMDAR-DREAM interaction 
The non-transcriptional effects of DREAM have been shown to regulate cell function 
and synaptic activity, mostly through a variety of specific protein-protein interactions (Rivas et 
al., 2011). The list of target proteins include cationic channels (An et al., 2000), membrane re-
ceptors (Rivas et al., 2009; Zhang et al., 2010) and membrane docking proteins (Wu et al., 
2010). A wide variety of mechanisms underlie synaptic changes associated with L-DOPA-
induced dyskinesia, including abnormal dendritic spine increases in denervated D2R-containing 
striatal neurons (Suárez et al., 2014) concomitant with abnormal increases in corticostriatal syn-
apses (Zhang et al., 2013). These synaptic changes may trigger the impaired synaptic plasticity 
and the persistent LTP found in the striatum of dyskinetic animals (Picconi et al., 2003). The 
increase in dyskinesias that we observe in DREAM-/- mice is also in line with these results, 
since inactivation of DREAM has been shown to strongly potentiate LTP in free-moving mice 
(Fontán-Lozano et al., 2009) and in hippocampal slices (Lilliehook et al., 2003) after HFS. 
However, several additional mechanisms could be related to DREAM-mediated changes in L-
DOPA-induced dyskinesias based on its presence in the cell body as discussed below. 
In addition to D1R stimulation, NMDAR activation plays an important role in dyskine-
sia, as treatment with NMDAR antagonists such as MK-801 or amantadine completely abol-
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ishes L-DOPA-induced dyskinesia (Papa et al., 1995; Blanchet et al., 2003). Interestingly, 
DREAM has been shown to diminish NMDAR activation (Wu et al., 2010; Zhang et al., 2010). 
DREAM knockdown with siRNAs significantly enhanced NMDAR-mediated currents in cul-
tured neurons, while overexpression of DREAM reduced NMDAR activation and its presence 
in the plasma membrane, indicating that DREAM modulates NMDAR function. Taken to-
gether, these data correlate well with our dyskinetic behavioral results. Inactivation of DREAM, 
which potentiates NMDAR-mediated currents, potentiates dyskinesia, while DREAM overex-
pression, which inhibits NMDAR function, decreases dyskinesia. Thus, it is possible that the 
inhibitory role of DREAM in L-DOPA-induced dyskinesia reported here could be partially re-
lated to the negative regulation exerted by DREAM on NMDAR. DREAM may directly inter-
act with the NR1 subunit preventing full activation of NMDAR complex as shown in cultured 
hippocampal neurons (Zhang et al., 2010). In addition, the documented capacity of DREAM to 
bind PSD-95 (Wu et al., 2010) impairing the recruitment of PSD-95 by D1 receptors (Porras et 
al., 2012) could contribute to the observed reduction of L-DOPA-induced dyskinesia. Disrup-
tion of the NMDAR-PSD-95 complex increases L-DOPA-induced dyskinesia (Gardoni et al., 
2006), probably by making PSD-95 available for interaction with D1R in the synaptic mem-
brane. Thus, displacement of the normal PSD-95 interactome from D1R due to increased 
DREAM levels could also contribute to the decrease in dyskinesia in daDREAM mice.  
2.4  Activation of DREAM decreases histone H3 phosphorylation 
Acetylated histone H3 is associated with active chromatin and gene transcription 
(Harrison et al., 2013), and this effect is synergistically potentiated by histone H3 phosphoryla-
tion (Cheung et al., 2000). Since phosphoacetylation of histone H3 correlates with the intensity 
of dyskinesia (Santini et al., 2007, 2009; Darmopil et al., 2009; Alcacer et al., 2012), the pres-
ence of increased phosphoacetylated histone H3 in DREAM-deficient animals is consistent 
with increased dynorphin-B and FosB expression and with increased L-DOPA-induced dyski-
nesia. On the contrary, in the presence of the daDREAM repressor, we observed decreased P-
AcH3, dynorphin-B, FosB and decreased L-DOPA-induced dyskinesia, as expected. In line 
with these observations, DREAM has been shown to inhibit transcription by blocking the 
CREB-CBP histone acetylase complex (Ledo et al., 2002). On the other hand, histone H3 phos-
phorylation depends on the stimulation of the D1R-pathway (Darmopil et al., 2009). Although 
it is possible that this occurs through the D1R/cAMP/PKA/DARPP-32 signaling pathway, it 
could also be mediated by the reported NMDAR-DREAM interaction through the NR1 receptor 
subunit (Zhang et al., 2010). 
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2.5  Activation of DREAM diminishes phosphorylation of AMPA receptors  
Although a direct DREAM and AMPA receptor interaction has not been described, it is 
possible that an indirect interaction occurs, since overexpression of DREAM significantly 
blocked L-DOPA-induced phosphorylation of the PKA substrate AMPA receptor subunit 
GluR1 at Ser845. GluR1-phosphorylation after L-DOPA treatment is in line with recent work 
from our laboratory (Suárez et al., 2014) showing dendritic spine re-growth in denervated stri-
atal areas. Indeed, spine regrowth leads to a recruitment of AMPA receptors to the post-
synaptic site (Malinow et al., 2000; Malenka, 2003; Shepherd and Huganir, 2007) in an activity
-dependent manner. Thus, under L-DOPA activation, there is AMPA receptors recruitment 
whereas no such recruitment is evident in basal conditions. This is also in line with our Western 
blot experiments, which revealed similar levels of GluR1-phosphorylation in basal conditions in 
all mutant mice, consistent with work of Wu and colleagues (2010). 
2.6  Calcium in L-DOPA-induced dyskinesia: DREAM regulation of voltage-
dependent calcium channels 
Finally, DREAM overexpression could control L-DOPA-induced dyskinesia develop-
ment through the regulation of voltage-dependent calcium channels. It has been shown that 
blockade of L-type calcium channels using the antagonist isradipine decreases dyskinetic symp-
toms (Schuster et al., 2009), while DREAM overexpression reduces the expression of the 
Cav1.2 gene, encoding the L-type calcium channel (Naranjo and Mellström, 2012) and de-
creases calcium permeability by direct protein-protein interaction with the L- and the T-type 
channel complexes (Thomsen et al., 2009; Anderson et al., 2010; Rivas et al., 2011). 
2.7  Alternative mechanisms of DREAM regulation 
We found a decrease in both dyskinetic symptoms and L-DOPA-induced molecular 
markers in the daDREAM mice but this decrease was not a complete blockade. This lack of 
complete blockade may be due to other alternative mechanisms that modulate DREAM biologi-
cal activity. Thus, in addition to αCREM and/or calcium interaction, other mechanisms can 
regulate DREAM function. These may include differential splicing (Spreafico et al., 2001), 
cleavage of N-terminal (Choi et al., 2003), palmitoylation (Takimoto et al., 2002) and phos-
phorylation by downstream kinases of the PI3 kinase pathway (Sanz et al., 2001). 
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Figure 39. Schematic diagram illustrating the regulatory role of DREAM in the transcriptional and non-
transcriptional mechanisms involved in LID. In the nucleus, the DREAM protein regulates dynorphin-B and 
possibly FosB expression (and subsequent LID) by anchoring to DRE sites located downstream from the transcrip-
tion initiation site of the DNA. This repression is released under conditions of Ca2+ and PKA-dependent interaction 
with phospho-CREM. In addition, outside the nucleus, DREAM could directly interact with NR1 subunit, inhibit-
ing activation of NMDA receptors, and with PSD-95, impairing its recruitment by D1R and decreasing the cAMP/
PKA signaling pathway. 
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In summary, this study demonstrates the inhibitory role of DREAM in L-DOPA-
induced dyskinesia as evidenced by reduction of dyskinetic symptoms in daDREAM mice and 
a potentiation of symptoms in DREAM-/- mice. In addition, we demonstrate that this action oc-
curs at least in part by transcriptional repression of target genes, although non-transcriptional 
mechanisms could also be involved. Thus, DREAM regulates dynorphin-B and possibly FosB 
expression, repressing their transcription by anchoring to DRE sites in the DNA, and reducing 
L-DOPA-induced dyskinesia. In addition, outside the nucleus DREAM could directly interact 
with the NR1 subunit and PSD-95, regulating activation of NMDAR and D1R (Figure 39). The 
findings we describe here validate DREAM as a novel therapeutic target against L-DOPA-
induced dyskinesia, and we propose that specific modulators of DREAM could be useful in al-
leviating L-DOPA-induced dyskinesia without interfering with the antiparkinsonian effect of L-
DOPA. However, other transcriptional and non-transcriptional targets of DREAM, as yet un-
characterized, could also be important, directly or indirectly, in the regulation of L-DOPA-
induced dyskinesia. Future genome-wide analysis during L-DOPA-induced dyskinesia in 
daDREAM and DREAM-/- mice might expand our understanding of the role of DREAM in L-
DOPA-induced dyskinesia. 
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The results obtained in the aforementioned studies lead us to the following conclusions: 
 
1.  In the striatum, Gαolf is primarily expressed in the striosomal compartment. Dopamine 
depletion by 6-OHDA lesion or genetic manipulation increases Gαolf protein and changes its 
expression pattern. 
2.  L-DOPA treatment restores both Gαolf protein levels and Gαolf expression pattern in the 
striatum of either 6-OHDA-lesioned or genetically manipulated mice. 
3.  Dopamine D1 receptor, but not D2 receptor, regulates Gαolf expression in the striatum. 
4.  Genetic modifications of DREAM, a downstream signaling element of D1R activation, do 
not affect Gαolf expression. 
5.  Genetic modifications of DREAM do not alter basal locomotor activity or motor 
coordination. 
6.  Overactivation of DREAM decreases L-DOPA-induced dyskinesia, while inactivation 
DREAM increases dyskinetic symptoms. 
7.  The therapeutic efficacy of L-DOPA is maintained despite genetic modifications of 
DREAM. 
8.  DREAM is expressed in both D1R-positive and D1R–negative projection neurons in the 
striatum.  
9.  DREAM levels in the striatum or substantia nigra are not affected by either 6-OHDA or L
-DOPA treatment. 
10. Overactivation of DREAM decreases the key molecular determinants of L-DOPA-
induced dyskinesias including FosB, dynorphin-B, P-AcH3 and P-GluR1, whereas DREAM 
inactivation increases them. 
In summary our data suggest that DREAM activators may be useful in alleviating L-DOPA-
induced dyskinesias without interfering with its therapeutic motor effects. 
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1. Genetic inactivation of dopamine D1 but not D2 receptors inhibits  
L-DOPA-induced dyskinesia and histone activation.   
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2. Activation of DREAM (downstream regulatory element antagonist modula-
tor), a calcium-binding protein, reduces L-DOPA-induced dyskinesia in mice 
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